mhtx_10k.htm

0001477932-23-002486.txt : 20230413 0001477932-23-002486.hdr.sgml : 20230413 20230413163857 ACCESSION NUMBER: 0001477932-23-002486 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230413 DATE AS OF CHANGE: 20230413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 23818819 BUSINESS ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-726-2107 MAIL ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 10-K 1 mhtx_10k.htm FORM 10-K mhtx_10k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______.

MANHATTAN SCIENTIFICS, INC.

(Name of small business issuer in its charter)

Delaware		000-28411		85-0460639
(State of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

244 Fifth Avenue, Suite 2341, New York, New York 10001

(Address of principal executive offices) (Zip code)

Issuer's telephone number: (212) 541-2405

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.001 par value

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the issuer as of June 30, 2022 was $4,726,599 based upon a closing price of $0.01 on June 30, 2022. For purposes of this computation, all executive officers, directors and 10% shareholders were deemed affiliates. Such a determination should not be construed as an admission that such 10% shareholders are affiliates.

As of April 7, 2023 there were 559,281,064 shares of common stock issued and outstanding.

TABLE OF CONTENTS

		PAGE
PART I

ITEM 1.	DESCRIPTION OF BUSINESS		3
ITEM 1A.	RISK FACTORS		5
ITEM 2.	DESCRIPTION OF PROPERTIES		6
ITEM 3.	LEGAL PROCEEDINGS		6
ITEM 4.	MINE SAFETY DISCLOSURES		6

PART II

ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES		7
ITEM 6.	SELECTED FINANCIAL DATA		9
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		9
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		12
ITEM 8.	FINANCIAL STATEMENTS		F-1
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE		13
ITEM 9A	CONTROLS AND PROCEDURES		13
ITEM 9B.	OTHER INFORMATION		14

PART III

ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS, PROMOTORS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT		15
ITEM 11.	EXECUTIVE COMPENSATION		16
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.		18
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE		18
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES		19
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES		20
	SIGNATURES		22

Table of Contents

PART I

Forward Looking Statements

This Form 10-K contains "forward-looking" statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "estimate," or "continue" or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate, competition within our chosen industry, including competition from much larger competitors, technological advances, our ability to obtain approval from the FDA or other governmental agencies and the failure by us to successfully develop business relationships. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization and mass production of, among other things, the advanced materials, the nanomedicine, successful protection of our licensed patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report. All written and oral forward-looking statements made subsequent to the date of this report and attributable to us or persons acting on our behalf are expressly qualified in their entirety by this section.

ITEM 1. DESCRIPTION OF BUSINESS

OVERVIEW

COMPANY HISTORY AND OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). The Company also holds a less than 5%, noncontrolling interest in Imagion Biosystems, Inc. (f/k/a Senior Scientific LLC) (“Imagion”).

Manhattan Scientifics, Inc. is focused on technology transfer and commercialization of these transformative technologies. The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields To achieve this goal, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with Los Alamos Laboratories in New Mexico.

In June 2008, we acquired Metallicum and its licensed patented technology. In January 2009, Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals.

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, Senior Scientific owned patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated. On November 17, 2016, Senior Scientific merged with and into Imagion, a Nevada company. Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On June 30, 2017, Imagion completed its initial public offering and listing on the Australian Stock Exchange (ASX). As of December 31, 2020, the Company owns 53,516,508 shares of Imagion (1,000,000 restricted shares), now resulting in a noncontrolling interest of approximately 5% of Imagion’s issued and outstanding common stock decreased primarily as a result of dilutive issuances by Imagion. Based upon Imagion’s latest trading price of approximately $0.11 per share, the fair value of the Imagion shares is approximately $5,875,000.

OUR DEVELOPMENT MODEL

Our goal has been to influence the future through the development of potentially life changing technologies. Our business model is to: (i) identify significant technologies, (ii) acquire them or the rights to them, (iii) secure the services of inventors, engineers or other staff who were instrumental in their creation, (iv) provide or contract for suitable work facilities, laboratories, and other aids where appropriate, (v) prototype the technologies to demonstrate "proof of principle" feasibility, (vi) secure patent and or other intellectual property protection, (vii) secure early customers for product trials where feasible and appropriate, and (viii) commercialize through licenses, sales or cooperative efforts with other manufacturing and distribution firms.

Since our technologies are still in their development phase, the need for operating and acquisition capital is a continuous concern requiring the ongoing efforts of our management. The Company’s success will depend in part on its ability to obtain patents and license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.

Table of Contents

We utilize the intellectual property sale/licensing model, and not a production model, though management is opportunistic and is open to explore all methods leading to commercializing our technologies. We intend to consider all appropriate avenues for the commercialization of our technologies.

The Company is not engaged in the business of investing, reinvesting, or trading in securities. The Company has not sold some of its investments on the open market.

DESCRIPTION OF TECHNOLOGIES

ADVANCED METALS

Our business model is based on licensing metals technology to metals manufacturers. Although competing commercial products are provided by existing specialty metals companies, the only competing processes for creating nanostructured metals are either limited or cannot be economically scaled. Metallicum does not yet face direct competition, but expects competition will emerge as the metal is commercialized.

In January 2009, we entered into a patent license agreement with Los Alamos National Security, LLC for the exclusive licensing use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. Pursuant to such agreement we provided a non-refundable fee and 2,000,000 shares of our common stock with a fair market value of $33,000. Additionally, we are required to pay an annual license fee of $10,000 starting in February 2010 and royalties on future net sales.

The nanostructured metals technology may have wide implications for use in the medical device and prosthetics industries including dental implants, replacements for hips, shoulders, knees and cardio vascular stents. In December 2008, a manufacturing joint venture partner in Albuquerque, NM received U.S. Food and Drug Administration 510(k) clearance to market nanostructured titanium metal dental implants using our technology. This clearance positions us closer to our goal of commercializing our technology for nanostructured metals. We are in talks with many of the key manufacturers of dental implants and have signed material testing agreements with several manufacturers.

In September 2009, the Company entered into a contract with Carpenter to sell certain nanostructured metal technologies acquired from Metallicum, its wholly owned subsidiary, to Carpenter and to provide sub-license rights to Carpenter covering license agreements that the Company has from Los Alamos Laboratories. In January 2013, the Company entered into a licensing agreement with a party granting certain licensing rights to the Company's nanostructured metal technology. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-up technical assistance and Carpenter provided a list of all customers and contacts. Following the return of the Company’s nanostructured metal technology, the Company has commenced exploring strategic alternatives for its Metallicum division. At this time we are exploring and working with partner companies in the fields of titanium dental implants, titanium and magnesium medical devices, high voltage aluminum conductors as well as oil and gas field applications.

INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT

In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years.

Our ability to compete depends in part on the protection of and our ability to defend our proprietary technology and on the goodwill associated with our trade names, service marks and other proprietary rights. However, we do not know if current laws will provide us with sufficient enough protection that others will not develop technologies similar or superior to ours, or that third parties will not copy or otherwise obtain or use our technologies without our authorization.

The success of our business will depend, in part, to identify technology, obtain patents, protect and enforce patents once issued and operate without infringing on the proprietary rights of others. Our success will also depend on our ability to maintain exclusive rights to trade secrets and proprietary technology we own are currently developing and will develop. We can give no assurance that any issued patents will provide us with competitive advantages or will not be challenged by others, or that the patents of others will not restrict our ability to conduct business.

In addition, we rely on certain technology licensed with a perpetual term from the Los Alamos National Laboratory and may be required to license additional technologies in the future. We do not know if these third-party licenses will be available or will continue to be available to us on acceptable commercial terms or at all. The inability to enter into and maintain any of these licenses could have a material adverse effect on our business, financial condition or results of our operations.

Table of Contents

Policing unauthorized use of our proprietary technology and other intellectual property rights could entail significant expense. In addition, we do not know if third parties will bring claims of copyright or trademark infringement against us or claim that our use of certain technologies violates a patent or other intellectual property. Any claims of infringement, with or without merit, could be time consuming and expensive to defend, result in costly litigation, divert management attention, require us to enter into costly royalty or licensing arrangements or prevent us from using important technologies or methods, any of which could have a material adverse effect on our business, financial condition or results of our operations.

SALES AND MARKETING

Although our technologies presently are in the development stage, we are engaged in an early commercialization program intended to facilitate the transition from development to licensing, manufacturing and/or sale. This program consists of preliminary dialogues with potential strategic partners, investors, manufacturers, potential licensees and/or purchasers.

COMPETITION

As a result of our licensed technology, we do not have any direct competitors in our advanced materials operations. We may, however, face competition from leading researchers and manufacturers worldwide that develop competing technology.

Competitors may successfully challenge our licensed technology, produce similar products that do not infringe our licensed technology or produce products in countries where we have not applied for intellectual property protection. Many of these competitors may have longer operating histories and significantly greater financial, marketing and other resources than we have. Furthermore, competitors may introduce new products that address our potential markets. Competition could have a material adverse effect on our business, financial condition and results of our operations.

The markets in which we compete are highly competitive and constantly evolving. We believe that the principal competitive factors in our technology markets include without limitation:

·	capitalization;
·	cost of product;
·	first to market with product in market segment;
·	strong intellectual portfolio;
·	product reliability;
·	strong customer base; and
·	strong manufacturing and supplier relationships.

CUSTOMERS AND SUPPLIERS

For the years ended December 31, 2022 and 2021, one customer generated all of our revenue. We did not have any significant suppliers.

EMPLOYEES

As of December 31, 2022, we had no full-time employees. We do not expect any significant change in the total number of employees in the near future. Most of our research and development work has been performed by employees of our various research and development independent contractors (see below). We have historically indirectly funded the salaries of these individuals through our contract research and development payments to their employers. Although not technically our employees, we have considered these individuals to be an integral part of our research and development team. None of our employees or contractors are members of any union or collective bargaining organization. We consider our relationships with independent contractor employees to be good.

As noted above, a significant portion of our research and development has been performed by independent contractors from whom we acquired or licensed certain technologies, and their various employees. Our independent contractors utilize a number of their own various employees to satisfy their research and development obligations to us, and their employees are considered to be part of our research and development team.

The Company’s officer and its directors spend substantially all of their time managing the Company’s business of developing and licensing its intellectual property in the metals industry.

ITEM 1A. RISK FACTORS

Item 1A Risk Factors

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

Table of Contents

ITEM 2. DESCRIPTION OF PROPERTIES

Our principal executive office is at 244 Fifth Avenue, Suite 2341, New York, New York, 10001. We lease approximately 300 square feet of office space on a month-to-month basis. The aggregate annual rent for this office space was $588 in 2022.

We believe our facilities are adequate for our current and planned business operations.

ITEM 3. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of December 31, 2022, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements other than the litigation described above which was subsequently settled.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

Table of Contents

PART II

ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

We are currently trading on the OTCQB operated by www.otcmarkets.com.

As of April 7, 2023, there were 559,281,064 shares of common stock of the issuer issued and outstanding and approximately 635 record shareholders.

DIVIDENDS

We have never paid any cash dividends. We presently intend to reinvest earnings, if any, to fund the development and expansion of our business and, therefore, do not anticipate paying cash dividends on our common stock in the foreseeable future. The declaration of cash dividends will be at the discretion of our board of directors and will depend upon our earnings, capital requirements, financial position, general economic conditions and other pertinent factors.

RECENT SALES OF UNREGISTERED SECURITIES

During the past two years, we have not issued unregistered shares of common stock, options, or warrants for the purchase of common stock.

Securities Authorized for Issuance under Equity Incentive Plans

The 2000 Plan is administered by a committee of two or more members of the Board of Directors or, if no committee is appointed, then by the Board of Directors. The 2000 Plan allows for the issuance of incentive stock options (which, pursuant to Section 422 of the Internal Revenue Code, can only be granted to employees), non-qualified stock options, stock appreciation rights, stock awards, or stock bonuses. The committee, or the Board of Directors if there is no committee, determines the type of option granted, the exercise price, the option term, which may be no more than ten years, terms and conditions of exercisability and methods of exercise. Options must vest within ten-years. Under the 2000 Plan, the exercise price may not be less than fair market value on the date of grant for the incentive stock options. The 2000 Plan also allows for the granting of Stock Appreciation Rights. No Stock Appreciation Rights have been granted. The number of shares under the 2000 Plan available for grant at December 31, 2022 was 18,869,763.

In November 2004, our Board of Directors adopted the 2004 Consultant Stock Plan (the "2004 Plan"). The purpose of this 2004 Consultant Stock Plan is to advance our interests by helping us obtain and retain the services of persons providing consulting services upon whose judgment, initiative, efforts and/or services we are substantially dependent, by offering to or providing those persons with incentives or inducements affording such persons an opportunity to become owners of our capital stock. We reserved 2,000,000 shares of our Common Stock for awards to be made under the 2004 Plan. We filed a registration statement on Form S-8 with the SEC on November 26, 2004 to register the shares underlying the 2004 plan. The 2004 Plan is administered by a committee of two or more members of the Board of Directors or, if no committee is appointed, then by the Board of Directors. The committee or the Board of Directors if there is no committee, determines who is eligible to receive awards under the plan, grant awards and interpret the 2004 Plan. The number of shares under the 2004 Plan available for grant at December 31, 2022 was 500,000.

On May 9, 2005, our Board of Directors adopted the 2005 Equity Compensation Plan (the "2005 Plan"). The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to our success, by offering them an opportunity to participate in the our future performance through awards of Options, the right to purchase Common Stock and Stock Bonuses. We reserved 10,000,000 shares of our Common Stock for awards to be made under the 2005 Plan. The 2005 Plan is administered by a committee of two or more members of the Board of Directors or, if no committee is appointed, then by the Board of Directors. The committee, or the Board of Directors if there is no committee, determines who is eligible to receive awards under the plan, grant awards and interpret the 2005 Plan. We filed a registration statement on Form S-8 with the SEC on June 8, 2005 to register the shares underlying the 2005 plan. The number of shares under the 2006 Plan available for grant at December 31, 2022 was -0-.

Table of Contents

In January 2015, our Board of Directors adopted the 2015 Incentive Stock Plan (the "2015 Plan"). The purpose of this Plan is to provide incentive stock options (which, pursuant to Section 422 of the Internal Revenue Code, can only be granted to employees), non-qualified stock options, stock appreciation rights, stock awards, or stock bonuses. The committee, or the Board of Directors if there is no committee, determines the type of option granted, the exercise price, the option term, which may be no more than ten years, terms and conditions of exercisability and methods of exercise. Options must vest within ten-years. Under the 2015 Plan, the exercise price may not be less than fair market value on the date of grant for the incentive stock options. The 2015 Plan also allows for the granting of Stock Appreciation Rights. No Stock Appreciation Rights have been granted. The number of shares under the 2015 Plan available for grant at December 31, 2022 was 4,000,000.

Set forth in the table below is information regarding awards made through compensation plans or arrangements through December 31, 2022.

Equity Compensation Plan Information

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)		Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans approved by security holders		—		—		—
Equity compensation plans not approved by security holders		—		—		23,369,763
Total		—		—	23,369,763

A summary of the Company’s stock option activity and related information is as follows:

	Number of Options			Exercise Price Per Share		Weighted Average Exercise Price		Number of Options Exercisable
Outstanding as of December 31, 2020		18,500,000							18,500,000
Granted		15,000,000			0.02		0.02		15,000,000
Exercised		-			-		-		-
Expired		(7,000,000	)		-		-		(7,000,000	)
Outstanding as of December 31, 2021		26,500,000							26,500,000
Granted		-			-		-		-
Exercised		-			-		-		-
Expired		-			-		-		-
Outstanding as of December 31, 2022		26,500,000							26,500,000

Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of December 31, 2021 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.02		15,500,000		7.40	$	0.02		15,500,000	$	0.02
$	0.05		3,000,000		2.50	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.60	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.50	$	0.14		3,000,000	$	0.14

The fair value for options granted were determined using the Black-Scholes option-pricing model. At December 31, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0.

Table of Contents

ITEM 6. SELECTED FINANCIAL DATA

N/A

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes appearing elsewhere in this Form 10-K.

OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). Manhattan Scientifics is focused on technology transfer and commercialization of these transformative technologies.

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company is actively seeking to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with Los Alamos Laboratories in New Mexico.

Metallicum

In June 2008, we acquired Metallicum and its licensed patented technology. We entered into a stock purchase agreement with Metallicum to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. On December 31, 2011, one milestone was met. Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. The Company anticipates royalty income as the nanotitanium is commercialized for use in medial prosthetics. Royalties will be 10% on sales of licensed dental products and an average of 5% in all other sales of licensed products. We expect to start earning royalties in 2023.

Imagion

As of December 31, 2022, Manhattan Scientifics presently owns 51,566,508 shares of Imagion, with a fair market value of approximately $839,000, based upon the closing price per share of Imagion common stock on the Australian Stock Exchange. The Company accounts for its investment in Imagion in accordance with ASC 825-10 and elected fair value option. We initially held 31% of the total issued and outstanding shares of Imagion and had one seat on the Board of Directors of Imagion. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of December 31, 2022, we hold approximately 5% of the total issued and outstanding shares of Imagion and no longer have a seat on the Board of Directors of Imagion.

Table of Contents

Novint

We made an investment in Novint Technologies Inc. (“Novint”) in 2001. Novint is currently engaged in the development and sale of 3D haptics products and equipment. Haptics refers to one’s sense of touch and Novint’s focus is in the consumer interactive computer gaming market. The Company owns 1,028,425 shares of Novint’s common stock. The fair value of the Novint shares are not recorded on the balance sheet as of December 31, 2022.

RESULTS OF OPERATIONS

YEAR ENDED DECEMBER 31, 2022 COMPARED TO YEAR ENDED DECEMBER 31, 2021

REVENUES. In the year ended December 31, 2022, we recognized $50,000 in revenue compared to $50,000 of revenue recognized for the year ended December 31, 2021.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $718,000 for the year ended December 31, 2022 compared with $727,000 for the year ended December 31, 2021. The primary decrease in general and administrative expense was the result of the increase in accounting expenses and legel expenses. During the year ended December 31, 2022, the officers and directors total compensation was $531,000 of which a total of $220,000 was paid to two individuals that are an officer and directors of the Company.

RESEARCH AND DEVELOPMENT. Research and development expenses consist of consultants and contractors. Research and development expenses were $11,000 for the year ended December 31, 2022 compared with $10,000 for the year ended December 31, 2021.

OTHER INCOME AND (EXPENSES). Total other expense for the year ended December 31, 2022 totaled $2,051,000, compared to the other expense of $2,952,000 for the year ended December 31, 2021. This is primarily attributable to the loss on fair value adjustments of its investment in Imagion and an decrease in interest.

NET LOSS. During the year ended December 31, 2022, the Company realized a net loss of $2,730,000, compared to a net net loss of $3,639,000 for the year ended December 31, 2021. This is primarily attributable to the loss on fair value adjustment of investment in Imagion, an increase in research and development.

LIQUIDITY AND PLAN OF OPERATIONS

Stockholders’ equity(deficit) totaled $(1,695,000) on December 31, 2022 and the working capital deficit was $(1,479,000) on such date. We had a decrease of $57,000 in cash and cash equivalents for the year ended December 31, 2022.

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including payroll, and professional services and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of December 31, 2022, we had $175,000 in cash. We believe our current cash position may not be sufficient to maintain our operations for the next twelve months. Accordingly, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

On October 17, 2019, we executed a secured note with our only independent director for $100,000 and a secured note with an unrelated party for $50,000. The secured notes were due on October 17, 2022. The Company agreed that the notes bear interest at 10% per annum, to be paid in advance with shares of Imagion Biosystems Limited common stock (“IBX”), calculated at $0.015 per share or 3,000,000 shares of IBX. As of December 31, 2022. We sold 950,000 shares of IBX common stock to raise funds for operations of $32,000.

CASH FLOW INFORMATION

The Company had cash and cash equivalents of approximately $175,000 and $232,000 at December 31, 2022 and 2021, respectively. This represents an decrease in cash of $57,000.

OPERATING ACTIVITIES

The Company used approximately $349,000 of cash for operating activities in the year ended December 31, 2022 as compared to using $421,000 of cash for operating activities in the year ended December 31, 2021. The reason for the decrease in cash used for operating activities is a decrease in the net loss and a decrease in the loss on fair value adjustment of investment.

Table of Contents

INVESTING ACTIVITIES

The Company received approximately $332,000 of cash for investing activities in the year ended December 31, 2022 as compared to receiving $300,000 of cash for investing activities in the year ended December 31, 2021. This increase in cash received in investing activities, is primarily attributed to proceeds from sale of investment of Imagion Biosystems shares in the current year.

FINANCING ACTIVITIES

The Company paid $40,000 and $0 of cash for financing activities in the year ended December 31, 2022 and 2021. During 2022, the Company made payments for notes payable totaling $40,000.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nano-structured materials developed by another company as a result of the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. The license has been fully amortized.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 and, may be required to pay royalties, as defined, to the licensors.

Revenue Recognition

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

Marketable Securities:

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the year ended December 31, 2021, no allowance was recorded for credit losses.

Table of Contents

Stock-Based Compensation:

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

Due from the Sale of Assets:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on remeasurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. On May 1, 2021 and 2020, the Company received $300,000 for sale of assets for a total of $1.2 million during the year ended December 31, 2019. The remaining $300,000 have been collected in 2022 and the Company received the full amount from the sale of assets.

Fair Value Measurements:

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

GOING CONCERN

As of December 31, 2022, the Company has an accumulated deficit of $71,250,000 and negative working capital of $1,479,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing of these financial statements. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

OFF BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a Small Reporting Company, we are not required to provide the information under Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Table of Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

REPORTS OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 3627)			F-2
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND 2021			F-3
CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021			F-4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021			F-5
CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021			F-6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS			F-7

F-1

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Manhattan Scientifics, Inc.:

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Manhattan Scientifics, Inc. (“the Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2022 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph Regarding Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has an accumulated deficit, negative cash flows form operations, and negative working capital, which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

/s/ Sadler, Gibb & Associates, LLC

We have served as the Company’s auditor since 2020.

Draper, UT

April 13, 2023

F-2

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS


	December 31,
	2022			2021

ASSETS
Current assets:
Cash and cash equivalents	$	175,000		$	232,000
Prepaid expenses		14,000			15,000
Due from the sale of assets - current portion		-			300,000
Total current assets		189,000			547,000

Investment in equity securities		839,000			2,901,000
Property and equipment, net		1,000			4,000
Other assets		2,000			2,000
Total assets	$	1,031,000		$	3,454,000

LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	119,000		$	102,000
Accrued expenses - related parties		1,439,000			1,129,000
Notes payable, net of discounts		110,000			130,000
Total current liabilities		1,668,000			1,361,000
Total liabilities		1,668,000			1,361,000

Commitments and Contingencies - Note 7		-			-

Series D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively		1,058,000			1,058,000

STOCKHOLDERS’ EQUITY (DEFICIT)
Capital stock $0.001 par value
Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively		-			-
Series B Convertible Preferred, authorized 250,000, 49,999 shares issued and outstanding, respectively		-			-
Series C Redeemable Convertible Preferred, authorized 14,000, no shares issued and outstanding, respectively		-			-
Common, authorized 950,000,000 shares, 559,281,064 shares issued, and outstanding, respectively		559,000			559,000
Additional paid-in-capital		68,996,000			68,996,000
Accumulated deficit		(71,250,000	)		(68,520,000	)
Total stockholders' equity (deficit)		(1,695,000	)		1,035,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	1,031,000		$	3,454,000

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS


	FOR THE YEAR ENDED
	DECEMBER 31,
	2022			2021

Revenue	$	50,000		$	50,000

Operating expenses:
General and administrative		718,000			727,000
Research and development		11,000			10,000

Total operating expenses		729,000			737,000

Loss from operations		(679,000	)		(687,000	)

Other income (expense):
Gain (Loss) on fair value adjustment of investments		(2,030,000	)		(2,974,000	)
Gain on settlement of legal fees		-			48,000
Interest expense		(21,000	)		(26,000	)
Total other income (expense)		(2,051,000	)		(2,952,000	)

NET LOSS	$	(2,730,000	)	$	(3,639,000	)

LOSS PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic and Diluted)		559,281,064			559,281,064

Basic and Diluted loss per common share (Basic and Diluted)	$	(0.00	)	$	(0.01	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE YEAR ENDED DECEMBER 31, 2022 and 2021


	Preferred Stock - Series B				Common Stock				Additional					Total Shareholders'
	$0.001 Par Value				$0.001 Par Value				Paid-In		Accumulated			Equity
	Shares		Amount		Shares		Amount		Capital		Deficit			(Deficit)

Balance
December 31, 2020		49,999		-		559,281,064		559,000		68,996,000		(64,881,000	)		4,674,000

Net loss		-		-		-		-		-		(3,639,000	)		(3,639,000	)

Balance
December 31, 2021		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(68,520,000	)	$	1,035,000

Net loss		-		-		-		-		-		(2,730,000	)		(2,730,000	)

Balance
December 31, 2022		49,999	$	-		559,281,064	$	559,000	$	68,996,000	$	(71,250,000	)	$	(1,695,000	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS


	FOR THE YEAR ENDED
	DECEMBER 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,730,000	)	$	(3,639,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,000			2,000
Loss on fair value adjustment of investments		2,030,000			2,974,000
Amortization of debt discount		20,000			26,000
Loss on settelement of legal fees		-			48,000
Changes in:
Prepaid expenses		1,000			(3,000	)
Accounts payable and accrued expenses		17,000			(105,000	)
Accounts payable and accrued expenses - related party		310,000			276,000

Net cash used in operating activities		(349,000	)		(421,000	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of investments		32,000			-
Proceeds from sale of assets held for sale		300,000			300,000

Net cash from investing activities		332,000			300,000

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments for note payable		(40,000	)		-
Net cash used in financing activities		(40,000	)		-

NET INCREASE IN CASH		(57,000	)		(121,000	)
CASH, BEGINNING OF PERIOD		232,000			353,000

CASH, END OF PERIOD	$	175,000		$	232,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 1 – BASIS OF PRESENTATION

Manhattan Scientifics, Inc., a Delaware corporation (formerly Grand Enterprises, Inc) (“Grand”) was established on July 31, 1992 and has a wholly-owned subsidiary: Metallicum, Inc. (“Metallicum”). On June 12, 2008, the Company acquired Metallicum, Inc, for 15,000,000 shares of Company’s common stock, Manhattan Scientifics, Inc., operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nano-technologies and nano-medicine. In this capacity, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The Company has a long standing relationship with Los Alamos Laboratories in New Mexico. During 2008, the Company refocused its efforts from the development of its fuel cell technologies to its current focus on the development of nanomaterials through the acquisition of Metallicum.

Metallicum is a nanotechnology start-up company located in Colorado. Metallicum Inc. has focused on the development and manufacture of nanostructured metals for medical implants and other applications. Metallicum intends to establish manufacturing partner relationships with major Fortune 500 metals companies and strategic partnering with significant customers in the medical device & prosthetics industries as well as in auto, truck, & aircraft manufacturing industries. Metallicum’s initial products include nanostructured bulk metals and alloys in the form of rod, bar, wire and foil. The Company conducts its operations primarily in the United States.

Manhattan Scientifics purchased Metallicum to acquire its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registrable under copyright or similar laws.

In January 2009, the Company entered into a patent license agreement with Los Alamos National Security, LLC for the exclusive licensing use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. Pursuant to such agreement the Company provided a non-refundable fee and 2,000,000 shares of common stock. Additionally, the Company is required to pay an annual license fee which started in February 2010 and royalties on future net sales.

In September 2009, the Company entered into a technology transfer agreement with Carpenter Technologies Corporation (“Carpenter”). Wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive technology transfer agreement from Manhattan Scientifics and the Los Alamos National Laboratory. The proprietary process will enable super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums. On February 11, 2015, the Company entered into a Settlement Agreement and Mutual General Releases (the "Settlement Agreement") with Carpenter Technology Corporation related to the agreement discussed in Note 7, pursuant to which the parties settled and released each other from any and all liabilities and claims related to the Carpenter Agreements.

On November 17, 2016, Senior Scientific merged with and into Imagion Biosystems, Inc., a Nevada corporation (“Imagion”). Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On June 30, 2017, Imagion completed an IPO and listing on the Australian Stock Exchange (ASX). As of December 31, 2022 , the Company owns 51,566,508 shares (1,000,000 restricted shares related to issued promissory notes interest) of Imagion, resulting in a noncontrolling interest of approximately 5% of Imagion’s issued and outstanding common stock. The Company elected to record the investment at fair value.

Manhattan Scientifics success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.

F-7

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

GOING CONCERN:

As of December 31, 2022, the Company has an accumulated deficit of 71,250,000 and negative working capital of $1,479,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing these financial statement. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

CASH AND CASH EQUIVALENTS:

The Company considers all highly liquid investments purchased with an original maturity of year or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of December 31, 2022, we had cash balances of $-0- exceeding the federally insured limits.

PROPERTY AND EQUIPMENT:

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.

F-8

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

INTANGIBLE ASSETS:

License Agreements

In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of 1the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors.

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. During May 2022 and 2021, the Company received $300,000 and $300,000 respectively and reduced the due from the sale of assets to the balance of $0. As of December 31, 2022, the Company received the full amount from the sale of assets.

MARKETABLE SECURITIES:

F-9

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

REVENUE RECOGNITION:

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE MEASUREMENTS:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash and cash equivalents (consisting of money market funds), short-term investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including prepaid expenses, accounts payable, accrued expenses and notes payables approximated fair value as of December 31, 2022 and December 31, 2021 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of December 31, 2022, the Company holds 51,566,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss on fair value adjustment of investments.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 and 2021, consisted of the following:

	Total fair value at December 31, 2022		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	839,000	$	839,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

F-10

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT

In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements was being amortized over the period of its estimated benefit period of 10 years. The license is fully amortized.

LEASES

The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease.

F-11

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2022 and 2021, 26,655,760 and 26,655,760, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the year ended December 31, 2021.

The following table shows the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2022 and 2021:

	The Years Ended
	December 31, 2022			December 31, 2021
Numerator:
Net loss	$	(2,730,000	)	$	(3,639,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

F-12

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

STOCK BASED COMPENSATION

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements.

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS

As of December 31, 2022, the Company owns 51,566,508 shares of Imagion, resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on December 31, 2022, approximately $0.01 per share, the fair value of the Imagion shares was approximately $839,000. During the year ended December 31, 2021, the Company recorded loss on fair value adjustment on its investment of $2,030,000.

Below is reconciliation for the changes to the investment in Imagion for the year ended December 31, 2022:

Balance as of December 31, 2020	$	2,901,000
Change in the unrealized fair value of securities		(2,030,000	)
Sales of securities		(32,000	)
Balance as of December 31, 2021	$	839,000

NOTE 4 – NOTES PAYABLE

On October 17, 2019, The Company executed two secured notes with a related party for $100,000. The secured notes were due on October 17, 2022. The notes bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 2 million shares of IBX common stock. The amortization of debt discount for the year ended December 31, 2022 and 2021 was $13,334 and $17,000, respectively.

On October 17, 2019, the Company executed a secured note with an individual for $50,000. The secured note was due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per shares with 1 million shares of IBX common stock. The amortization of debt discount for the years ended December 31, 2022 and 2021 was $6,666 and $9,000, respectively.

F-13

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000.

On September 30, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000.

Notes payable as of December 31, 2022 were as follows:

Notes payable	$	130,000
Less: Discounts on notes payable		(20,000	)
Notes payable, net of discounts	$	110,000

NOTE 5 – CAPTIAL TRANSACTIONS

Preferred Stock

The Company has a total of 1,000,000 shares of authorized preferred shares which are segregated into four classes of preferred stock.

The Company has 182,525 authorized shares of convertible, redeemable, 10 percent cumulative, Class A, Preferred Stock with $0.001 par value. One Class A, Preferred share is convertible into 50 restricted common shares and will be entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Series A Preferred stock could be converted at the time of the vote. Class A, Preferred Stock is redeemable by the Company at $15 per share. Upon liquidation the holders of Series A Preferred stock will be entitled to be paid out of the assets available for distribution of the corporation an amount equal to $10 per share, before any payment will be made to the common shareholders. As of December 31, 2022 and 2021, no shares of Preferred Stock were issued and outstanding.

The Company has 250,000 authorized shares of Class B, Preferred Stock with $0.001 par value. As of December 31, 2022 and 2021, 49,999 and 49,999 shares of Preferred Stock were issued and outstanding, respectively. Class B preferred shares are convertible at a rate of 1 Series B preferred share to 10 common shares.

The Company has 14,000 authorized shares of redeemable, convertible, Class C, Preferred Stock with $100 stated value. Class C, Preferred Stock is not entitled to receive dividends unless dividends are paid on common stock. Upon liquidation Class C, Preferred Stock shall be treated as if it were converted to common stock prior to liquidation. Class C, Preferred Stock is convertible at $100 divided by the 10 day average closing price of common stock. The Class C, Preferred Stock is redeemable by the Company at the stated value. As of December 31, 2022 and 2021, no shares of Preferred Stock were issued and outstanding.

On November 5, 2013, the Company entered into a Conversion Agreement with Marvin Maslow (the "Holder") pursuant to which the Company agreed to convert $1,057,608 of debt (the "Debt"), including principal and interest, currently owed to Holder into 105,761 shares of Series D Preferred Shares of the Company. The Debt had been outstanding since 2007.

The above transactions were approved by the Board of Directors of the Company. The Series D Preferred Stock does not pay dividends and does not have a liquidation preference. The Holder of the Series D Preferred Stock will be entitled to 20 votes for each share of common stock that the Series D Preferred Stock are convertible into. The Series D Preferred Stock has a conversion price of $0.055 (the “Conversion Price”) and a stated value of $10.00 (the “Stated Value”) per share. Each share of Series D Preferred Stock is convertible, at the option of the Holder, into such number of shares of common stock of the Company as determined by dividing Stated Value by the Conversion Price.

Holder may only convert the Series D Preferred Stock upon certain Convertible Promissory Notes, whether presently outstanding or to be issued, issued to three accredited investors (the "Note Investors") in accordance with those certain Convertible Note Purchase Agreements between the Company and the Note Investors dated April 3, 2013, have either (i) been converted in full or in part by the Note Investors into shares of common stock of the Company, (ii) the Note Investors have sold or assigned all or a part of their Convertible Promissory Notes to third parties, or (iii) the Note Investors have been paid in full or in part. The Holder will only be permitted to convert such number of Series D Preferred Stock equal to the pro rata amount of the Convertible Promissory Notes converted, assigned or paid. In the event the Note Investors agree in writing that these restrictions may be terminated, then the Holder will be entitled to convert the Series D Preferred Stock at the Holder’s election and the above restrictions will be null and void. Additionally, Holder may not convert the Series D Preferred Stock until the ten day average daily trading volume is greater than $20,000. As of the date of this filing, this has not occurred yet.

F-14

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

In the event the Holder terminates its consulting agreement or violates a non-compete covenant, then the Series D Preferred Shares shall be returned to the Company for cancellation and the Company shall be obligated on the Debt. As the Series D Preferred Stock is conditionally redeemable, the Company has recorded the Series D Preferred Stock as mezzanine equity in the accompanying consolidated balance sheet.

The Company has 447,804 and 447,804 undesignated blank check preferred stock, $0.001 par value, authorized as of December 31, 2022 and 2021. The preferred shares are to be issued in such series and to have such rights, preferences, and designation as determine by the Board of Directors of the Company.

Common Stock

The Company has a total of 950,000,000 shares of authorized common shares. As of December 31, 2022 and 2021, 559,281,064 and 559,281,064 shares of common stock were issued and outstanding, respectively.

Stock Activity during 2022 and 2021

During the year ended December 31, 2022 and 2021, the Company had not issued common stock.

Options

On March 22, 2021, the Company entered into a settlement with a third party, which the Company granted 15,000,000 shares of common stock options to purchase 15,000,000 shares of common stock at an exercise price of $0.0154. The options price was based on the closing market price of common stock on October 1, 2020. The Settlement is for the Employment Agreement with a third party, dated January 12, 2015 to which the Company agreed to issued common shares.

At December 31, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable			Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000			0.07		2.84		18,500,000		$	-
Granted		15,000,000			0.02		9.68		15,000,000			15,000
Exercised		-			-		-		-
Expired		(7,000,000	)	$	0.07		-		(7,000,000	)		-
Outstanding as of December 31, 2021		26,500,000			0.04		6.06		26,500,000			15,000
Granted		-			-		-		-			-
Exercised		-			-		-		-
Expired		-			-		-		-			-
Outstanding as of December 31, 2022		26,500,000		$	0.04		4.97		26,500,000		$	0

F-15

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of December 31, 2022 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.02		15,500,000		7.55	$	0.02		15,500,000	$	0.02
$	0.05		3,000,000		2.50	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.60	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.50	$	0.14		3,000,000	$	0.14

The fair value for options granted were determined using the Black-Scholes option-pricing model.

The Company did not recognize compensation expense during the year ended December 31, 2022.

NOTE 6 – INCOME TAXES

The provision for income taxes on the statements of operations consists of $-0- and $-0- for the years ended December 31, 2022 and 2021, respectively. Deferred tax assets are comprised of the following at December 31:

	2022			2021
Net operating loss carryforward	$	13,501,350		$	12,704,000
Temporary differences		6,988,000			6,988,000
Less valuation allowance		(20,489,350	)		(19,692,000	)
Deferred tax asset, net		-			-

Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. At December 31, 2022 and 2021, management determined that realization of these benefits is not assured and has provided a valuation allowance for the entire amount of such benefits. At December 31, 2022 and 2021, net operating loss carryforwards were approximately $47,275,000 and $47,275,000, respectively, for federal tax purposes that expire at various dates through 2031 and for state tax purposes expire through 2025.

Utilization of net operating loss carryforwards may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986, as amended, and similar state regulations. The annual limitation may result in the expiration of substantial net operating loss carryforwards before utilization.

For December 31, 2022 and 2021, the provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2021 and 2020) to income taxes as follows:

	2022			2021
Tax benefit computed at 21%	$	(737,100	)	$	982,530	)
Change in valuation allowance		737,100			982,530
Change in carryovers and tax attributes		-			-
Income tax provision	$	-		$	-

NOTE 7 – LICENSE AGREEMENT

On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the years ended December 31, 2022 and 2021, the Company received $50,000 and $50,000, respectively, as a minimum royalty payment.

F-16

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

NOTE 8 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

NOTE 9 – RELATED PARTY TRANSACTIONS

As of December 31, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,439,000 and $1,129,000.

As of December 31, 2022, the amounts are due to the Company’s sole officer for compensation $362,000 and the chairman of the board for compensation of $996,000 and the members of the board of directors of $81,000.

NOTE 10 – SUBSEQUENT EVENTS

In January 2023, the Company signed an agreement with one of its noteholders to pay one million IBX shares with a strike price of $0.003 per share USD, the transfer was made on January 26, 2023, in addition to $10,000 in cash for repayment on March 22, 2023. The remaining balance of $20,000 will be paid later.

F-17

Table of Contents

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS

None

ITEM 9T. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Our principal executive and principal financial officers have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a – 15(e) and 15d – 15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") that arc designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods required under the SEC's rules and forms and that the information is gathered and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(c) as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report due to the reasons described below.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission.

Management's Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(t) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

1. Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

2. Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with the authorization of our management and directors; and

3. Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. Based on this assessment, management concluded that the Company did not maintain effective internal controls over financial reporting as a result of the identified material weakness in our internal control over financial reporting described below. In making this assessment, management used the framework set forth in the report entitled Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO (2013). The COSO framework summarizes each of the components of a company's internal control system, including (i) the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication. and (v) monitoring.

Table of Contents

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement or the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting as or December 31, 2021:

Resources: As of December 31, 2021, we had no full-time employees in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures. The Company lacks sufficient monitoring and review controls with respect to accounting for complex transactions.

Management's Remediation Initiatives

We plan to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions. We also plan to add an audit committee financial expert to our board and create an audit committee made up of our independent directors.

(b) Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting during this fiscal quarter that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

Table of Contents

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

The names, ages and biographical information of each of our directors and executive officers as of March 27, 2020 are set forth below. There are no existing family relationships between or among any of our executive officers or directors.

NAME	AGE	POSITION

Emmanuel Tsoupanarias	70	President and Chief Executive Officer, Director
Frank Georgiou	72	Director
Marvin Maslow	85	Chairman of the Board

Members of the Board serve until the next annual meeting of stockholders and until their successors are elected and qualified. Officers are appointed by and serve at the discretion of the Board. There are no family relationships among any of our directors or officers.

None of our directors or executive officers has, during the past ten years:

·	been convicted in a criminal proceeding and none of our directors or executive officers is subject to a pending criminal proceeding,
·	been subject to any order, judgment, or decree not subsequently reversed, suspended or vacated of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities, futures, commodities or banking activities, or
·	been found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

EMMANUEL TSOUPANARIAS has served as our chief executive officer and director since November 1, 2007. Mr. Tsoupanarias is the president, founder and editor of FuelCellsWorks.com, a weekly trade publication that has become the voice of the fuel cell industry. He is internationally recognized as an expert in fuel cell development. Prior to his tenure at FuelCellsWorks.com, Mr. Tsoupanarias was an executive in the power generation manufacturing sector. From 1992 to 2007 Mr. Tsoupanarias has served as a Project Manager in the power generation sector and from 2000 has served as a consultant in the fuel cell industry. His technical and engineering background and his 11-year tenure as the Company’s CEO qualify him for the Company’s Board.

FRANK GEORGIOU has served as a director since October 2007. Since 1993, Mr. Georgiou has been the President of Three Diamond Diner Corp., a private company that owns and operates the Mount Kisco Coach Diner. He is the former President of the Upper New York Pangregorian, a consortium of restaurant owners. Mr. Georgiou’s business experience as president of a private company is valuable to the Company’s Board.

MARVIN MASLOW served as the CEO of Manhattan Scientifics from January 1998 until November 2007. On March 13, 2015, Mr. Maslow was appointed as a director of the Company. From June 1990 through September 1996, Mr. Maslow served as chief executive officer of Projectavision, Inc., a company he co-founded to develop and market video projection technology. For more than 20 years, Mr. Maslow has been President of Normandie Capital Corp., a private investment and consulting company. Mr. Maslow is credited with the starting up and financing of more than 20 enterprises during his career. Mr. Maslow received an A.A.S. degree from the Rochester Institute of Technology in 1957 and an honorable discharge from the U.S. Army Signal Corps in 1963. Mr. Maslow serves as a paid consultant to the Company, attends board meetings and serves as a special advisor to the Board of Directors. He also serves as a Manager of the Company’s Senior Scientifics LLC subsidiary.

Table of Contents

SECCTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors, and persons who own more than ten percent of our common stock to file reports of ownership and change in ownership with the Securities and Exchange Commission and the exchange on which the common stock is listed for trading. Executive officers, directors and more than ten percent stockholders are required by regulations promulgated under the Exchange Act to furnish us with copies of all Section 16(a) reports filed. Based solely on our review of copies of the Section 16(a) reports filed for the fiscal year ended December 31, 2021, we believe that our executive officers, directors and ten percent stockholders complied with all reporting requirements applicable to them.

CODE OF ETHICS

On March 31, 2005, we adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the Company’s Code of Ethics can be viewed obtained free of charge by sending a written request to the attention of the Company’s Chief Executive Officer, Emmanuel Tsoupanarias at 244 Fifth Avenue, Suite 2341, New York, New York, 10001.

CORPORATE GOVERNANCE

We do not have a separately-designated standing audit committee. The entire Board of Directors of the Company acts as the audit committee. The Board of Directors of the Company has determined that it does not have an "audit committee financial expert" as such term is defined in the rules adopted by the SEC requiring companies to disclose whether or not at least one member of the audit committee is an "audit committee financial expert." The Board of Directors believes that the aggregate technical, commercial and financial experience of its members, together with their knowledge of the Company, provides the Board with the ability to monitor and direct the goals of the Company and to protect the best interests of its shareholders. Four of the five members of the Board of Directors are "independent," as that term is defined in Section 10A(m) of the Securities Exchange Act of 1934, and that the members' independence qualifies it to monitor the performance of management, the public disclosures by the Company of its financial condition and performance, the Company's internal accounting operations and its independent auditors. In addition, the Board of Directors is authorized to engage independent financial consultants, auditors and counsel whenever it believes it is necessary and appropriate.

ITEM 11. EXECUTIVE COMPENSATION

The following tables set forth all compensation awarded by us to our executive officers for the fiscal years ended December 31, 2022 and 2021. Other than the Employment Agreement entered into between the Company and Emmanuel Tsoupanarias, our CEO, we do not have employment agreements with any of our other officers.

Name	Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Changes in Pension Value and Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)

Emmanuel Tsoupanarias	2022		186,000		--		--		--		--		--		--		186,000
CEO and Director	2021		186,000		--		--		--		--		--		--		186,000

Prior to entering an Employment Agreement with the Company on March 28, 2013, Mr. Emmanuel Tsoupanarias, our Chief Executive Officer, did not have an employment agreement. His salary, was originally set at $100,000, was set by the Board of Directors in 2007. On March 28, 2013, the Company entered into an Employment Agreement with Emmanuel Tsoupanarias, our CEO. The agreement is for a term of five years and Mr. Tsoupanarias shall receive an annual salary of $150,000 per year and additional cash incentive consideration as determined by the Board. Effective January 1, 2015, the Company renewed the agreement for a period of ten years with automatic extensions for one-year periods thereafter. His salary remains at $150,000 per year and cash incentive of $3,000 per month . In the event the employment agreement is terminated by the Company without cause, then the Mr. Tsoupanarias shall receive 50% of the base salary remaining on the term and all options and other securities he would have been entitled to for an additional three months shall vest.

The independent members of the Company’s board of directors, acting as a compensation committee, reviewed the compensation policies and practices relating to the compensation provided to the Company’s employees to determine whether such policies and practices are reasonably likely to have a material adverse effect on the Company. Based on the review and the compensation paid by the Company to its only employee, the Company determined that any risks associated with the Company’s compensation practices were not reasonably likely to have a material adverse effect on the Company.

Table of Contents

Director Compensation

For the year ended December 31, 2022, for their service as directors, each of the directors received $1,250 per quarter.

Compensation Committee Interlocks and Insider Participation

Our entire board currently acts as our compensation committee. Emmanuel Tsoupanarias is the sole executive officer of our company. No member of the compensation committee is employed by or serving as a member of the board of directors or compensation committee of any entity that has one or more of its executive officers serving as a member of our board.

OUTSTANDING EQUITY AWARDS

Name	Grant Date	Number of Securities Underlying Unexercised Warrants (#) Exercisable		Number of Securities Underlying Unexercised Warrants (#) Unexercisable (1)		Warrant Exercise Price ($)		Warrant Expiration Date


Emmanuel Tsoupanarias, Director and CEO	06/30/2014		500,000		-	$	0.140	06/30/2024

Frank Georgiou, Director	06/30/2014		500,000		-	$	0.140	06/30/2024

Chris Theoharis, Former Director (2)	06/30/2014		500,000		-	$	0.140	06/30/2024

Leonard Friedman, Former Director (1)	06/30/2014		500,000		-	$	0.140	06/30/2024

Marvin Maslow, Chairman of the Board	06/30/2014		500,000		-	$	0.140	06/30/2024

Leonard Friedman, Former Director (1)	06/30/2015		500,000		-	$	0.05	06/30/2025

Marvin Maslow, Chairman of the Board	06/30/2015		500,000		-	$	0.05	06/30/2025

Saraklis, Inc. (Emmanuel Tsoupanarias)	06/30/2015		500,000		-	$	0.05	06/30/2025

Frank Georgiou, Director	06/30/2015		500,000		-	$	0.05	06/30/2025

Chris Theoharis, Former Director (2)	06/30/2015		500,000		-	$	0.05	06/30/2025

Leonard Friedman, Former Director (1)	06/30/2016		500,000		-	$	0.06	06/30/2026

Marvin Maslow, Chairman of the Board	06/30/2016		500,000		-	$	0.06	06/30/2026

Saraklis, Inc. (Emmanuel Tsoupanarias)	06/30/2016		500,000		-	$	0.06	06/30/2026

Frank Georgiou, Director	06/30/2016		500,000		-	$	0.06	06/30/2026

Chris Theoharis, Former Director (2)	06/30/2016		500,000		-	$	0.06	06/30/2026

(1) Mr. Friedman resigned as a director on January 3, 2018.

(2) Mr. Theoharis resigned as a director on July 10, 2017.

Grant of Plan Based Awards

No plan-based awards were made during the fiscal year ended December 31, 2022.

Table of Contents

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth, as of March 27, 2023, the names, addresses and number of shares of common stock beneficially owned by (i) all persons known to us to be the beneficial owners of more than 5% of the outstanding shares of common stock, (ii) each of our directors, (iii) each of our executive officers, and (iv) all of our directors and executive officers as a group. Except as indicated, each beneficial owner listed exercises sole voting power and sole dispositive power over the shares beneficially owned. Share ownership in each case includes shares issuable upon exercise of options exercisable within 60 days of the date of this Annual Report that would be required to be reported pursuant to Rule 13d-3 of the Securities Exchange Act of 1934 for purposes of computing the percentage of common stock owned by such person but not for purposes of computing the percentage owned by any other person. Unless otherwise indicated, the address of the below-listed persons is our address, 244 Avenue, Suite 2341, New York, New York 10001.

Name and Address of Beneficial Owner	Number of Shares Beneficially Owned		Percent of Class (1)

Emmanuel Tsoupanarias (2)		30,430,773		5.4	%
Frank Georgiou (3)		30,937,075		5.5	%

Marvin Maslow (4)(5)		54,982,546		9.8	%
Directors and Executive Officers as a group (3 persons)		116,350,394		20.8	%

Total		116,350,394		20.8	%

____________

(1) This tabular information is intended to conform to Rule 13d-3 promulgated under the Securities Exchange Act of 1934 relating to the determination of beneficial ownership of securities. The percent of class is based on 559,281,064 shares and, for each beneficial owner, gives effect to the exercise of warrants or options exercisable within 60 days of the date of this table owned, in each case, by the person or group whose percentage ownership is set forth herein.

(2) Includes 10,930,773 shares owned by Saraklis Inc. ("Saraklis"), a corporation controlled by Mr. Tsoupanarias, 12,000,000 shares owned by Saraklis Consultant Inc., a corporation controlled by Mr. Tsoupanarias, options for Saraklis to purchase 7,500,000 shares.

(3) Includes 28,437,075 shares of Common Stock owned by Mr. Georgiou, 1,000,000 shares of Common Stock owned by relatives of Mr. Georgiou, options to purchase 1,500,000 shares.

(4) Includes 28,028,273 shares of Common Stock, options to purchase 1,500,000 shares, 6,000,000 shares owned by Normandie New Mexico Corp., a corporation controlled 100% by Mr. Maslow, options for Mr. Maslow to purchase 1,500,000 shares.

(5) Includes 105,761 shares of Series D Preferred Stock on an as converted basis. The Series D Preferred Stock has a conversion price of $0.055 and a stated value of $10.00 per share for a total of 19,229,273 common shares. Each share of Series D Preferred Stock is convertible into such number of shares of common stock of the Company as determined by dividing stated value by the conversion price.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

None.

Table of Contents

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

INDEPENDENT AUDITOR FEES

The following is a summary of the fees billed to us by our independent auditors for the fiscal years ended December 31, 2022 and December 31, 2021:

Fee Category	2022		2021

Audit and audit related fees	$	29,000	$	29,000
Tax fees		-		-
Other fees		-		-
Total fees	$	29,000	$	29,000

Audit Fees. Consists of aggregate fees billed for professional services rendered for the audit of our consolidated financial statements and review of the interim consolidated financial statements included in quarterly reports and services that are normally provided by our auditors in connection with statutory and regulatory filings or engagements.

Tax Fees. Consists of aggregate fees billed for professional services for tax compliance, tax advice and tax planning. These services include assistance regarding federal and state tax compliance. There were no tax services provided in fiscal years ended December 31, 2022 and 2021.

Other Fees. Consists of fees for products and services other than the services reported above. There were no management consulting services provided in fiscal years ended December 31, 2022 and 2021.

We do not currently have an Audit Committee. Our full Board of Directors considers whether the provision of these services is compatible with maintaining the auditor's independence, and has determined such services

BOARD OF DIRECTORS POLICY ON PRE-APPROVAL OF SERVICES OF INDEPENDENT AUDITORS

The Board of Directors’ policy is to pre-approve all audit and permissible non-audit services provided by the independent auditors on a case-by-case basis. These services may include audit services, audit-related services, tax services and other services.

Table of Contents

ITEM 15. EXHIBITS

(a) EXHIBITS

Exhibit Number		Description of Exhibit

2.1		Agreement and Plan of Reorganization (1)
2.2		Agreement and Plan of Merger (1)
3.1		Certificate of Incorporation dated August 1, 1995 (12)
3.2		Certificate of Amendment to Certificate of Incorporation dated January 8, 1998 (12)
3.3		Bylaws (1)
3.4		Certificate of Amendment of Certificate of Incorporation dated January 16, 2001 (12)
3.5		Certificate of Amendment of Certificate of Incorporation dated August 8, 2007 (12)
4.1		Certificate of Designation, Preferences and Rights of Series B Preferred Stock (12)
4.2		Amended Certificate of Designation, Preferences and Rights of Series B Preferred Stock (12)
4.3		Certificate of Designation, Preferences and Rights of Series C Preferred Stock (12)
4.4		Amended Certificate of Designation, Preferences and Rights of Series C Preferred Stock (2)
4.5		Certificate of Designation for the Series D Preferred Stock (14)
10.1		Manhattan Scientifics, Inc. 1998 Stock Option Plan (1)
10.2		Manhattan Scientifics, Inc. 2000 Equity Incentive Plan (5)
10.3		2004 Consultant Stock Plan (6)
10.4		Manhattan Scientifics 2005 Equity Incentive Plan (8)
10.5		Technology Transfer Agreement by and between Carpenter Technology Corporation and Manhattan Scientifics, Inc, effective as of the 12th day of September 2009 (7)
10.6		Acquisition Option Agreement by and among Senior Scientific LLC, Edward R. Flynn, Ph.D., Scientific Nanomedicine, Inc. and Manhattan Scientifics, Inc. (10)
10.7		Stock Purchase Agreement, dated as of June 12, 2008, among Manhattan Scientifics, Inc., Metallicum, Inc., and the shareholders of Metallicum (9)
10.8		Settlement and Memorandum of Agreement among Marvin Maslow, Jack B. Harrod and Manhattan Scientifics, Inc. (9)
10.9		Patent License Agreement Between Los Alamos National Security, LLC and Manhattan Scientifics, Inc. (10)
10.10		Agreement and Plan of Reorganization by and among the Company, Scientific Nanomedicine, Inc., Edward, R. Flynn and Edward R. Flynn and Maureen A. Flynn, as Co-Trustees of the Edward R. Flynn and Maureen A. Flynn Revocable Trust u/t/a dated 10/25/2006. (11)
10.11		Purchase Agreement by and among the Company, Senior Scientific LLC and Edward R. Flynn. (11)
10.12		Consulting Agreement dated June 1, 2011 between Manhattan Scientifics Inc. and V. Gerald Grafe (12)
10.13		Employment Agreement dated March 28, 2013 between Manhattan Scientifics Inc. and Emmanuel Tsoupanarias (12)
10.14		Consulting Agreement between Normandie New Mexico Corp. and Manhattan Scientifics Inc. dated October 1, 2009 (12)
10.15		Amendment to the Consulting Agreement between Normandie New Mexico Corp. and Manhattan Scientifics Inc. dated October 1, 2009 (12)
10.16		Settlement Agreement and Mutual General Releases by and between Manhattan Scientifics, Inc. and Carpenter Technology Corporation dated February 11, 2015 (22)
14.1		Code of Ethics (9)
16.1		Letter from L.L. Bradford & Company, LLC (21)
21.1		List of Subsidiaries (12)
31.1		Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) and 15d- 14(a)
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
EX-101.INS**		Inline XBRL INSTANCE DOCUMENT
EX-101.SCH**		Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
EX-101.CAL**		Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
EX-101.DEF**		Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
EX-101.LAB**		Inline XBRL TAXONOMY EXTENSION LABELS LINKBASE
EX-101.PRE**		Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
EX-104**		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Table of Contents

______________

(1) Incorporated by reference to the registrant's Form 10-SB filed with the Commission on December 8, 1999.

(2) Incorporated by reference to the registrant's Form 10-QSB filed with the Commission on August 14, 2000 for the period ended June 30, 2000.

(3) Incorporated by reference as Amendment No. 2 to the registrant's Form 10-SB filed with Commission on February 9, 2000.

(4) Reserved.

(5) Incorporated by reference to the registrant's proxy statement filed on Schedule 14C filed with the Commission on December 26, 2000.

(6) Incorporated by reference to the registrant's registration statement filed on Form S-8 filed with the Commission on November 26, 2004.

(7) Incorporated by reference to Amendment No. 2 to the registrant’s Form 10-Q/A for the period ended September 30, 2009 filed with the Commission on October 4, 2010.

(8) Incorporated by reference to the registrant's registration statement in Form S-8 filed with the Commission on June 8, 2005.

(9) Incorporated by reference to the registrant's Form 10-K filed with the Commission on April 9, 2010.

(10) Incorporated by reference to the registrant’s Form 10-K/A filed with the Commission on March 25, 2011.

(11) Incorporated by reference to the registrant's Form 8-K filed with the Commission on June 6, 2011.

(12) Incorporated by reference to the registrant's Form 10-K filed with the Commission on March 30, 2012.

(13) Incorporated by reference to the registrant's Form 8-K filed with the Commission on April 9, 2013

(14) Incorporated by reference to the registrant's Form 8-K filed with the Commission on November 8, 2013

(15) Incorporated by reference to the registrant's Form 8-K filed with the Commission on January 31, 2014

(16) Incorporated by reference to the registrant's Form 8-K filed with the Commission on February 12, 2014

(17) Incorporated by reference to the registrant's Form 8-K filed with the Commission on November 18, 2014

(18) Incorporated by reference to the registrant's Form 8-K filed with the Commission on December 11, 2014

(19) Incorporated by reference to the registrant's Form 8-K filed with the Commission on January 5, 2015

(20) Incorporated by reference to the registrant's Form 8-K filed with the Commission on January 20, 2015

(21) Incorporated by reference to the registrant's Form 8-K filed with the Commission on February 9, 2015

(22) Incorporated by reference to the registrant's Form 8-K filed with the Commission on February 19, 2015

(23) Incorporated by reference to the registrant's Form 8-K filed with the Commission on March 19, 2015

(24) Incorporated by reference to the registrant's Form 8-K filed with the Commission on April 20, 2015

(25) Incorporated by reference to the registrant's Form 8-K filed with the Commission on May 7, 2015

(26) Incorporated by reference to the registrant's Form 8-K filed with the Commission on August 28, 2015

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this April 13, 2023.

	MANHATTAN SCIENTIFICS, INC.

	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer

In accordance with the Exchange Act, this report has been signed below by the following persons on April 13, 2023 on behalf of the registrant and in the capacities indicated.

Signature		Title

/s/ Emmanuel Tsoupanarias		Chief Executive Officer, President, Director
Emmanuel Tsoupanarias		(Principal Executive, Financial and Accounting Officer)

/s/ Frank Georgiou		Director
Frank Georgiou

/s/ Marvin Maslow		Chairman of the Board
Marvin Maslow

EX-31.1 2 mhtx_311.htm CERTIFICATION mhtx_311.htm

EXHIBIT 31.1

Certifications

I, Emmanuel Tsoupanarias, certify that:

1.	I have reviewed this annual report on Form 10-K of Manhattan Scientifics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 13, 2023	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(Principal Executive, Financial and Accounting Officer)

EX-32.1 3 mhtx_321.htm CERTIFICATION mhtx_321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Manhattan Scientifics, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emmanuel Tsoupanarias, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 13, 2023

By:

/s/ Emmanuel Tsoupanarias

Emmanuel Tsoupanarias

Chief Executive Officer (Principal Executive and,

Financial and Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Manhattan Scientifics, Inc. and will be retained by Manhattan Scientifics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request .

EX-101.SCH 4 mhtx-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - CAPITAL TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - COMMITMENTS AND CONTIGENCIES link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - CAPITAL TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - CAPITAL TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - CAPITAL TRANSACTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mhtx-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity File Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Security 12b Title Local Phone Number Auditor Firm Id Auditor Name Auditor Location CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Class A Convertible Preferred Stock [Member] Series B convertible preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] ASSETS Current assets: Cash and cash equivalents Prepaid expenses Due from the sale of assets - current portion Total current assets [Assets, Current] Investment in equity securities Property and equipment, net Other assets Total assets [Assets] LIABILITIES Current liabilities: Accounts payable and accrued expenses Accrued expenses - related parties Notes payable, net of discounts Total current liabilities [Liabilities, Current] Total liabilities [Liabilities] Commitments and Contingencies - Note 7 Series D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively STOCKHOLDERS' EQUITY (DEFICIT) Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively Common, authorized 950,000,000 shares, 559,281,064 shares issued, and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity (deficit) [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) [Liabilities and Equity] Class D Convertible Mandatory Redeemable Preferred Stock [Member] Class B Convertible Preferred Stock [Member] Capital stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Revenue Operating expenses: General and administrative Research and development Total operating expenses [Operating Costs and Expenses] Loss from operations [Operating Income (Loss)] Other income (expense): Gain (Loss) on fair value adjustment of investments Gain on settlement of legal fees [Gain (Loss) on Extinguishment of Debt] Interest expense [Interest Expense] Total other income (expense) [Nonoperating Income (Expense)] NET LOSS [Net Income (Loss) Attributable to Parent] LOSS PER COMMON SHARE: Weighted average number of common shares outstanding (Basic and Diluted) Basic and Diluted loss per common share (Basic and Diluted) CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Equity Components [Axis] Preferred Stock Series B Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Net loss Balance, shares Balance, amount CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on fair value adjustment of investments [Gain (Loss) on Sale of Investments] Amortization of debt discount Changes in: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Accounts payable and accrued expenses - related party Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from the sale of investments Proceeds from sale of assets held for sale Net cash from investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Repayments for note payable [Repayments of Notes Payable] Net cash used in financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE IN CASH [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] CASH, BEGINNING OF PERIOD [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid BASIS OF PRESENTATION BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Significant Accounting Policies [Text Block] INVESTMENT IN IMAGION BIOSYSTEMS INVESTMENT IN IMAGION BIOSYSTEMS Equity Method Investments and Joint Ventures Disclosure [Text Block] NOTES PAYABLE NOTES PAYABLE Debt Disclosure [Text Block] CAPITAL TRANSACTIONS NOTE 5 - CAPITAL TRANSACTIONS INCOME TAXES INCOME TAXES Income Tax Disclosure [Text Block] LICENSE AGREEMENT LICENSE AGREEMENT [LICENSE AGREEMENT] COMMITMENTS AND CONTIGENCIES COMMITMENTS AND CONTIGENCIES Commitments and Contingencies Disclosure [Text Block] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Schedule of Subsequent Events [Table Text Block] BASIS OF CONSOLIDATION GOING CONCERN USE OF ESTIMATES CASH AND CASH EQUIVALENTS CASH CONCENTRATION PROPERTY AND EQUIPMENT INTANGIBLE ASSETS DUE FROM THE SALE OF ASSETS MARKETABLE SECURITIES REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT LEASES INCOME TAXES Income Tax, Policy [Policy Text Block] BASIC AND DILUTED EARNINGS (LOSS) PER SHARE STOCK BASED COMPENSATION RECENT ACCOUNTING PRONOUNCEMENTS Schedule of fair value measurement of assets and liabilities Schedule of basic and diluted earnings (loss) per share Schedule of changes to the investment in Imagion Schedule of debt discount Summary of Company's stock option activity Exercise prices and weighted-average contractual lives of stock options outstanding Summary of deferred tax assets Provision for income taxes differs from amount computed by applying U.S. federal statutory tax rate Plan Name [Axis] Related Party [Axis] Award Date Axis Patent license agreement [Member] EX-101.CAL 6 mhtx-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 mhtx-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 mhtx-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2022	Apr. 07, 2023	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	MANHATTAN SCIENTIFICS, INC.
Entity Central Index Key	0001099132
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		559,281,064
Entity Public Float			$ 4,726,599
Document Annual Report	true
Document Transition Report	false
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	85-0460639
Entity Interactive Data Current	Yes
Entity File Number	000-28411
Entity Address Address Line 1	244 Fifth Ave
Entity Address Address Line 2	Suite 2341
Entity Address City Or Town	New York
Entity Address State Or Province	NY
Entity Address Postal Zip Code	10001
City Area Code	212
Security 12b Title	Common Stock, $0.001 par value
Local Phone Number	541-2405
Auditor Firm Id	3627
Auditor Name	Sadler, Gibb & Associates, LLC
Auditor Location	Draper, UT

XML 10 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 175,000	$ 232,000
Prepaid expenses	14,000	15,000
Due from the sale of assets - current portion	0	300,000
Total current assets	189,000	547,000
Investment in equity securities	839,000	2,901,000
Property and equipment, net	1,000	4,000
Other assets	2,000	2,000
Total assets	1,031,000	3,454,000
Current liabilities:
Accounts payable and accrued expenses	119,000	102,000
Accrued expenses - related parties	1,439,000	1,129,000
Notes payable, net of discounts	110,000	130,000
Total current liabilities	1,668,000	1,361,000
Total liabilities	1,668,000	1,361,000
Series D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively	1,058,000	1,058,000
STOCKHOLDERS' EQUITY (DEFICIT)
Common, authorized 950,000,000 shares, 559,281,064 shares issued, and outstanding, respectively	559,000	559,000
Additional paid-in-capital	68,996,000	68,996,000
Accumulated deficit	(71,250,000)	(68,520,000)
Total stockholders' equity (deficit)	(1,695,000)	1,035,000
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)	1,031,000	3,454,000
Class A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively	0	0
Series B convertible preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively	0	0
Class C Redeemable Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively	$ 0	$ 0

XML 11 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Capital stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	559,281,064	559,281,064
Common stock, shares outstanding	559,281,064	559,281,064
Preferred stock, shares authorized	1,000,000
Preferred stock, shares outstanding	0	0
Class A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	182,525	182,525
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class C Redeemable Convertible Preferred Stock [Member]
Preferred stock, shares authorized	14,000	14,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class D Convertible Mandatory Redeemable Preferred Stock [Member]
Preferred stock, shares authorized	105,761	105,761
Preferred stock, shares issued	105,761	105,761
Preferred stock, shares outstanding	105,761	105,761
Class B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	49,999	49,999
Preferred stock, shares outstanding	49,999	49,999

XML 12 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 50,000	$ 50,000
Operating expenses:
General and administrative	718,000	727,000
Research and development	11,000	10,000
Total operating expenses	729,000	737,000
Loss from operations	(679,000)	(687,000)
Other income (expense):
Gain (Loss) on fair value adjustment of investments	(2,030,000)	(2,974,000)
Gain on settlement of legal fees	0	48,000
Interest expense	(21,000)	(26,000)
Total other income (expense)	(2,051,000)	(2,952,000)
NET LOSS	$ (2,730,000)	$ (3,639,000)
LOSS PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic and Diluted)	559,281,064	559,281,064
Basic and Diluted loss per common share (Basic and Diluted)	$ (0.00)	$ (0.01)

XML 13 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Preferred Stock Series B	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2020		49,999	559,281,064
Balance, amount at Dec. 31, 2020	$ 4,674,000	$ 0	$ 559,000	$ 68,996,000	$ (64,881,000)
Net loss	(3,639,000)	$ 0	$ 0	0	(3,639,000)
Balance, shares at Dec. 31, 2021		49,999	559,281,064
Balance, amount at Dec. 31, 2021	1,035,000	$ 0	$ 559,000	68,996,000	(68,520,000)
Net loss	(2,730,000)	$ 0	$ 0	0	(2,730,000)
Balance, shares at Dec. 31, 2022		49,999	559,281,064
Balance, amount at Dec. 31, 2022	$ (1,695,000)	$ 0	$ 559,000	$ 68,996,000	$ (71,250,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,730,000)	$ (3,639,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,000	2,000
Loss on fair value adjustment of investments	2,030,000	2,974,000
Amortization of debt discount	20,000	26,000
Gain on settlement of legal fees	0	48,000
Changes in:
Prepaid expenses	1,000	(3,000)
Accounts payable and accrued expenses	17,000	(105,000)
Accounts payable and accrued expenses - related party	310,000	276,000
Net cash used in operating activities	(349,000)	(421,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of investments	32,000	0
Proceeds from sale of assets held for sale	300,000	300,000
Net cash from investing activities	332,000	300,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments for note payable	(40,000)	0
Net cash used in financing activities	(40,000)	0
NET INCREASE IN CASH	(57,000)	(121,000)
CASH, BEGINNING OF PERIOD	232,000	353,000
CASH, END OF PERIOD	175,000	232,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	0
Income taxes paid	$ 0	$ 0

XML 15 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

12 Months Ended

Dec. 31, 2022

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE 1 – BASIS OF PRESENTATION

XML 16 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

12 Months Ended

Dec. 31, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

GOING CONCERN:

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

CASH AND CASH EQUIVALENTS:

The Company considers all highly liquid investments purchased with an original maturity of year or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

CASH CONCENTRATION:

PROPERTY AND EQUIPMENT:

INTANGIBLE ASSETS:

License Agreements

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. During May 2022 and 2021, the Company received $300,000 and $300,000 respectively and reduced the due from the sale of assets to the balance of $0. As of December 31, 2022, the Company received the full amount from the sale of assets.

MARKETABLE SECURITIES:

REVENUE RECOGNITION:

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE MEASUREMENTS:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 and 2021, consisted of the following:

	Total fair value at December 31, 2022		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	839,000	$	839,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT

In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements was being amortized over the period of its estimated benefit period of 10 years. The license is fully amortized.

LEASES

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2022 and 2021:

	The Years Ended
	December 31, 2022			December 31, 2021
Numerator:
Net loss	$	(2,730,000	)	$	(3,639,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

STOCK BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 17 R9.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS

12 Months Ended

Dec. 31, 2022

INVESTMENT IN IMAGION BIOSYSTEMS

INVESTMENT IN IMAGION BIOSYSTEMS

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS

Below is reconciliation for the changes to the investment in Imagion for the year ended December 31, 2022:

Balance as of December 31, 2020	$	2,901,000
Change in the unrealized fair value of securities		(2,030,000	)
Sales of securities		(32,000	)
Balance as of December 31, 2021	$	839,000

XML 18 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

12 Months Ended

Dec. 31, 2022

NOTES PAYABLE

NOTES PAYABLE

NOTE 4 – NOTES PAYABLE

On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000.

On September 30, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000.

Notes payable as of December 31, 2022 were as follows:

Notes payable	$	130,000
Less: Discounts on notes payable		(20,000	)
Notes payable, net of discounts	$	110,000

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 19 R11.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS

12 Months Ended

Dec. 31, 2022

CAPITAL TRANSACTIONS

NOTE 5 - CAPITAL TRANSACTIONS

NOTE 5 – CAPTIAL TRANSACTIONS

Preferred Stock

The Company has a total of 1,000,000 shares of authorized preferred shares which are segregated into four classes of preferred stock.

Common Stock

Stock Activity during 2022 and 2021

During the year ended December 31, 2022 and 2021, the Company had not issued common stock.

Options

At December 31, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable			Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000			0.07		2.84		18,500,000		$	-
Granted		15,000,000			0.02		9.68		15,000,000			15,000
Exercised		-			-		-		-
Expired		(7,000,000	)	$	0.07		-		(7,000,000	)		-
Outstanding as of December 31, 2021		26,500,000			0.04		6.06		26,500,000			15,000
Granted		-			-		-		-			-
Exercised		-			-		-		-
Expired		-			-		-		-			-
Outstanding as of December 31, 2022		26,500,000		$	0.04		4.97		26,500,000		$	0

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of December 31, 2022 are as follows:

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.02		15,500,000		7.55	$	0.02		15,500,000	$	0.02
$	0.05		3,000,000		2.50	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.60	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.50	$	0.14		3,000,000	$	0.14

The fair value for options granted were determined using the Black-Scholes option-pricing model.

The Company did not recognize compensation expense during the year ended December 31, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 20 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Dec. 31, 2022

INCOME TAXES

INCOME TAXES

NOTE 6 – INCOME TAXES

	2022			2021
Net operating loss carryforward	$	13,501,350		$	12,704,000
Temporary differences		6,988,000			6,988,000
Less valuation allowance		(20,489,350	)		(19,692,000	)
Deferred tax asset, net		-			-

For December 31, 2022 and 2021, the provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2021 and 2020) to income taxes as follows:

	2022			2021
Tax benefit computed at 21%	$	(737,100	)	$	982,530	)
Change in valuation allowance		737,100			982,530
Change in carryovers and tax attributes		-			-
Income tax provision	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 21 R13.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT

12 Months Ended

Dec. 31, 2022

LICENSE AGREEMENT

LICENSE AGREEMENT

NOTE 7 – LICENSE AGREEMENT

During the years ended December 31, 2022 and 2021, the Company received $50,000 and $50,000, respectively, as a minimum royalty payment.

XML 22 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTIGENCIES

12 Months Ended

Dec. 31, 2022

COMMITMENTS AND CONTIGENCIES

COMMITMENTS AND CONTIGENCIES

NOTE 8 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

XML 23 R15.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2022

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

As of December 31, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,439,000 and $1,129,000.

XML 24 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2022

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

XML 25 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)

12 Months Ended

Dec. 31, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION

GOING CONCERN

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investments purchased with an original maturity of year or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

CASH CONCENTRATION

PROPERTY AND EQUIPMENT

INTANGIBLE ASSETS

License Agreements

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. During May 2022 and 2021, the Company received $300,000 and $300,000 respectively and reduced the due from the sale of assets to the balance of $0. As of December 31, 2022, the Company received the full amount from the sale of assets.

MARKETABLE SECURITIES

REVENUE RECOGNITION

The revenue was generated was from minimum royalty payments from the license agreement.

FAIR VALUE OF FINANCIAL INSTRUMENTS

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 and 2021, consisted of the following:

	Total fair value at December 31, 2022		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	839,000	$	839,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT

In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements was being amortized over the period of its estimated benefit period of 10 years. The license is fully amortized.

LEASES

INCOME TAXES

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE

The following table shows the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2022 and 2021:

	The Years Ended
	December 31, 2022			December 31, 2021
Numerator:
Net loss	$	(2,730,000	)	$	(3,639,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

STOCK BASED COMPENSATION

RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

XML 26 R18.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)

12 Months Ended

Dec. 31, 2022

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

Schedule of fair value measurement of assets and liabilities

	Total fair value at December 31, 2022		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	839,000	$	839,000	$	-	$	-

	Total fair value at December 31, 2021		Quoted prices in active markets for identical assets (Level1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	2,901,000	$	2,901,000	$	-	$	-

Schedule of basic and diluted earnings (loss) per share

	The Years Ended
	December 31, 2022			December 31, 2021
Numerator:
Net loss	$	(2,730,000	)	$	(3,639,000	)

Denominator:
Weighted-average basic shares outstanding		559,281,064			559,281,064
Effect of dilutive securities		-			-
Weighted-average diluted shares		559,281,064			559,281,064

Basic earnings (loss) per share	$	(0.00	)	$	(0.01	)
Diluted earnings (loss) per share	$	(0.00	)	$	(0.01	)

XML 27 R19.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Tables)

12 Months Ended

Dec. 31, 2022

INVESTMENT IN IMAGION BIOSYSTEMS

Schedule of changes to the investment in Imagion

Balance as of December 31, 2020	$	2,901,000
Change in the unrealized fair value of securities		(2,030,000	)
Sales of securities		(32,000	)
Balance as of December 31, 2021	$	839,000

XML 28 R20.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

12 Months Ended

Dec. 31, 2022

NOTES PAYABLE

Schedule of debt discount

Notes payable	$	130,000
Less: Discounts on notes payable		(20,000	)
Notes payable, net of discounts	$	110,000

XML 29 R21.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Tables)

12 Months Ended

Dec. 31, 2022

CAPITAL TRANSACTIONS

Summary of Company's stock option activity

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Life		Number of Options Exercisable			Aggregate Intrinsic Value
Outstanding as of December 31, 2020		18,500,000			0.07		2.84		18,500,000		$	-
Granted		15,000,000			0.02		9.68		15,000,000			15,000
Exercised		-			-		-		-
Expired		(7,000,000	)	$	0.07		-		(7,000,000	)		-
Outstanding as of December 31, 2021		26,500,000			0.04		6.06		26,500,000			15,000
Granted		-			-		-		-			-
Exercised		-			-		-		-
Expired		-			-		-		-			-
Outstanding as of December 31, 2022		26,500,000		$	0.04		4.97		26,500,000		$	0

Exercise prices and weighted-average contractual lives of stock options outstanding

				Options Outstanding				Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.02		15,500,000		7.55	$	0.02		15,500,000	$	0.02
$	0.05		3,000,000		2.50	$	0.05		3,000,000	$	0.05
$	0.06		5,000,000		2.60	$	0.06		5,000,000	$	0.06
$	0.14		3,000,000		1.50	$	0.14		3,000,000	$	0.14

XML 30 R22.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2022

INCOME TAXES

Summary of deferred tax assets

	2022			2021
Net operating loss carryforward	$	13,501,350		$	12,704,000
Temporary differences		6,988,000			6,988,000
Less valuation allowance		(20,489,350	)		(19,692,000	)
Deferred tax asset, net		-			-

Provision for income taxes differs from amount computed by applying U.S. federal statutory tax rate

	2022			2021
Tax benefit computed at 21%	$	(737,100	)	$	982,530	)
Change in valuation allowance		737,100			982,530
Change in carryovers and tax attributes		-			-
Income tax provision	$	-		$	-

XML 31 R23.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Details Narrative) - shares		1 Months Ended
BASIS OF PRESENTATION (Details Narrative) - shares	Jun. 12, 2008	Jan. 31, 2009	Dec. 31, 2022
Imagion Biosystems, Inc. [Member]
Common stock owned shares			51,566,508
Issued and outstanding shares noncontrolling interest			5.00%
Restricted shares related to issued promissory notes interest			1,000,000
Metallicum, Inc [Member] \| In 2008 [Member]
Common stock, shares acquired	15,000,000
Patent license agreement [Member] \| Los Alamos National Security LLC [Member]
Common stock shares issued		2,000,000

XML 32 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Investment in equity securities	$ 839,000	$ 2,901,000
Significant other observable inputs [Member] \| Level 2 [Member]
Investment in equity securities	0	0
Significant other observable inputs [Member] \| Level 1 [Member]
Investment in equity securities	839,000	2,901,000
Significant unobservable inputs [Member] \| Level 3 [Member]
Investment in equity securities	$ 0	$ 0

XML 33 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss	$ (2,730,000)	$ (3,639,000)
Denominator:
Weighted-average basic shares outstanding	559,281,064	559,281,064
Effect of dilutive securities	0	0
Weighted-average diluted shares	559,281,064	559,281,064
Basic earnings (loss) per share	$ (0.00)	$ (0.01)
Diluted earnings (loss) per share	$ (0.00)	$ (0.01)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 34 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	May 31, 2020	Jun. 30, 2008	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2009
Common stock owned shares			51,566,508
Proceeds from sale of assets held for sale	$ 300,000		$ 300,000	$ 300,000	$ 300,000
Accumulated deficit			(71,250,000)	$ (68,520,000)
Working capital deficit			1,479,000
Cash FDIC insured amount			250,000
Cash exceeding insured amount			$ 0
Adjusted asset valuation						$ 1,200,000
Sale of asset					$ 1,200,000
Income Tax Examination, Likelihood of Unfavorable Settlement			An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Weighted average number diluted shares			26,655,760	26,655,760
Minimum [Member]
Property and equipment useful lives			3 years
Maximum [Member]
Property and equipment useful lives			10 years
In 2008 [Member] \| Metallicum, Inc [Member]
Licenses purchased price		$ 305,000
Amortization period		10 years
In 2009 [Member] \| Los Alamos National Security LLC [Member] \| Patent license agreement [Member]
Fair value of common stock issued							$ 2,000,000
Annual license fee							$ 10,000

XML 35 R27.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details) - USD ($)	12 Months Ended
INVESTMENT IN IMAGION BIOSYSTEMS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
INVESTMENT IN IMAGION BIOSYSTEMS
Balance as of December 31, 2020	$ 2,901,000
Change in the unrealized fair value of securities	(2,030,000)	$ (2,974,000)
Sales of securities	(32,000)
Balance as of December 31, 2021	$ 839,000	$ 2,901,000

XML 36 R28.htm IDEA: XBRL DOCUMENT

INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) - Imagion Biosystems, Inc. [Member]	Dec. 31, 2022 USD ($) $ / shares shares
Common stock owned shares	51,566,508
Trading price per share \| $ / shares	$ 0.01
Fair value of investment \| $	$ 839,000
Change in unrealized gain in investment	2,030,000

XML 37 R29.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details)	Dec. 31, 2022 USD ($)
NOTES PAYABLE
Notes payable	$ 130,000
Less: Discounts on notes payable	(20,000)
Notes payable, net of discounts	$ 110,000

XML 38 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended		12 Months Ended
	Sep. 30, 2022	Oct. 17, 2019	Dec. 31, 2022	Dec. 31, 2021
Note payable repayments			$ 40,000	$ 0
Amortization of Debt Discount			20,000	26,000
Note Payable [Member]
Note payable repayments	$ 10,000
Notes payable	140,000
Notes payable balance reduced amount	150,000
Note Payable 1 [Member]
Note payable repayments	30,000
Notes payable balance reduced amount	$ 110,000
Related Party [Member]
Secured note		$ 100,000
Price per share		$ 0.015
Shares issued in advance for debt		2
Interest rate		10.00%
Amortization of Debt Discount			13,334	17,000
Debt due date		Oct. 17, 2022
Individuals [Member]
Secured note		$ 50,000
Price per share		$ 0.015
Shares issued in advance for debt		1
Interest rate		10.00%
Amortization of Debt Discount			$ 6,666	$ 9,000
Debt due date		Oct. 17, 2022

XML 39 R31.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details) - USD ($)	12 Months Ended
CAPITAL TRANSACTIONS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CAPITAL TRANSACTIONS
Number of Options, Outstanding Beginning Balance	26,500,000	18,500,000
Number of Options, Granted	0	15,000,000
Number of Options, Exercised	0	0
Number of Options, Expired	0	(7,000,000)
Number of Options, Outstanding Ending Balance	26,500,000	26,500,000
Weighted Average Life
Weighted Average Life, Outstanding Beginning Balance	6 years 21 days	2 years 10 months 2 days
Weighted Average Life, Granted	0 years	9 years 8 months 4 days
Weighted Average Life, Outstanding Ending Balance	4 years 11 months 19 days	6 years 21 days
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.04	$ 0.07
Weighted Average Exercise Price, Granted	0.00	0.02
Weighted Average Exercise Price, Exercised	0.00	0.00
Weighted Average Exercise Price, Expired	0.00	0.07
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.04	$ 0.04
Number of Options Exercisable
Number of Options Exercisable, Outstanding Beginning Balance	26,500,000	18,500,000
Number of Options Exercisable, Granted	0	15,000,000
Number of Options Exercisable, Excercised	0	0
Number of Options Exercisable, Expired	0	(7,000,000)
Number of Options Exercisable, Outstanding Ending Balance	26,500,000	26,500,000
Aggregate intrinsic value
Aggregate intrinsic value, Beginning Balance	$ 15,000	$ 0
Aggregate intrinsic value, Granted	0	15,000
Aggregate intrinsic value, Expired	0	0
Aggregate intrinsic value, Ending Balance	$ 0	$ 15,000

XML 40 R32.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details 1) - $ / shares	12 Months Ended
CAPITAL TRANSACTIONS (Details 1) - $ / shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of Options, Outstanding Beginning Balance	26,500,000	26,500,000	18,500,000
Weighted Average Exercise Price	$ 0.00	$ 0.00
Number of Options Exercisable, Outstanding Beginning Balance	26,500,000	26,500,000	18,500,000
Exercise Price 0.02 [Member]
Number of Options, Outstanding Beginning Balance	15,500,000
Weighted Average Remaining Contractual Life	7 years 6 months 18 days
Weighted Average Exercise Price	$ 0.02
Number of Options Exercisable, Outstanding Beginning Balance	15,500,000
Weighted Average Exercise Price, exercisable	$ 0.02
Exercise Price 0.05 [Member]
Number of Options, Outstanding Beginning Balance	3,000,000
Weighted Average Remaining Contractual Life	2 years 6 months
Weighted Average Exercise Price	$ 0.05
Number of Options Exercisable, Outstanding Beginning Balance	3,000,000
Weighted Average Exercise Price, exercisable	$ 0.05
Exercise Price 0.06 [Member]
Number of Options, Outstanding Beginning Balance	5,000,000
Weighted Average Remaining Contractual Life	2 years 7 months 6 days
Weighted Average Exercise Price	$ 0.06
Number of Options Exercisable, Outstanding Beginning Balance	5,000,000
Weighted Average Exercise Price, exercisable	$ 0.06
Exercise Price 0.14 [Member]
Number of Options, Outstanding Beginning Balance	3,000,000
Weighted Average Remaining Contractual Life	1 year 6 months
Weighted Average Exercise Price	$ 0.14
Number of Options Exercisable, Outstanding Beginning Balance	3,000,000
Weighted Average Exercise Price, exercisable	$ 0.14

XML 41 R33.htm IDEA: XBRL DOCUMENT

CAPITAL TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
CAPITAL TRANSACTIONS (Details Narrative) - USD ($)	Nov. 05, 2013	Mar. 22, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common Stock, shares authorized			950,000,000	950,000,000
Common Stock, shares issued			559,281,064	559,281,064
Common Stock, shares outstanding			559,281,064	559,281,064
Preferred stock shares outstanding			0	0
Preferred stock, shares authorized			1,000,000
Number of Options, Outstanding Beginning Balance			26,500,000	26,500,000	18,500,000
Preferred stock, par value			$ 0.001	$ 0.001
Stock Option [Member]
Number of Options, Outstanding Beginning Balance			26,500,000
Exercisable price		$ 0.0154
Option to purchase common stock		15,000,000
Stock options available for grant		15,000,000
Class B Preferred Stock [Member]
Preferred stock shares outstanding			49,999	49,999
Preferred stock shares issued			49,999	49,999
Preferred stock, shares authorized			250,000	250,000
Preferred stock, par value			$ 0.001	$ 0.001
Convertible preferred stock, terms of conversion feature			Class B preferred shares are convertible at a rate of 1 Series B preferred share to 10 common shares
Class C Preferred Stock [Member]
Preferred stock shares outstanding			0	0
Preferred stock shares issued			0	0
Preferred stock, shares authorized			14,000	14,000
Preferred stock, par value			$ 100	$ 100
Convertible preferred stock, terms of conversion feature			Class C, Preferred Stock is convertible at $100 divided by the 10 day average closing price of common stock
Preferred stock liquidation preference description			Upon liquidation Class C, Preferred Stock shall be treated as if it were converted to common stock prior to liquidation
Class A Preferred Stock [Member]
Preferred stock, shares authorized			182,525	182,525
Preferred stock, par value			$ 0.001	$ 0.001
Cumulative preferred stock interest rate			10.00%	10.00%
Convertible preferred stock, terms of conversion feature			One Class A, Preferred share is convertible into 50 restricted common shares and will be entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Series A Preferred stock could be converted at the time of the vote
Conversion price			$ 15
Preferred stock redemption terms			Class A, Preferred Stock is redeemable by the Company at $15 per share
Preferred stock liquidation preference description			Upon liquidation the holders of Series A Preferred stock will be entitled to be paid out of the assets available for distribution of the corporation an amount equal to $10 per share, before any payment will be made to the common shareholders
Undesignated blank check [Member]
Preferred stock, shares authorized			447,804	447,804
Preferred stock, par value			$ 0.001	$ 0.001
Coversion Agreement [Member] \| Holder [Member] \| Class D Preferred Stock [Member]
Preferred stock shares outstanding	105,761
Preferred stock shares issued	105,761
Preferred stock, par value	$ 10.00
Common stock converted amount	$ 1,057,608
Conversion price	$ 0.055
Voting rights, description			The Holder of the Series D Preferred Stock will be entitled to 20 votes for each share of common stock that the Series D Preferred Stock are convertible into
Convertible preferred stock terms of conversion			Additionally, Holder may not convert the Series D Preferred Stock until the ten day average daily trading volume is greater than $20,000

XML 42 R34.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES
Net operating loss carryforward	$ 13,501,350	$ 12,704,000
Temporary differences	6,988,000	6,988,000
Less valuation allowance	(20,489,350)	(19,692,000)
Deferred tax asset, net	$ 0	$ 0

XML 43 R35.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES
Tax benefit computed at 21%	$ (737,100)	$ (982,530)
Change in valuation allowance	737,100	982,530
Change in carryovers and tax attributes	0	0
Income tax provision	$ 0	$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 44 R36.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES
Provision for income taxes	$ 0	$ 0
Operating loss carryforwards net	$ 47,275,000	$ 47,275,000
Provision for income taxes, rates	21.00%	21.00%
Federal net operating loss carryforwards expiration date	through 2031
State net operating loss carryforwards expiration date	through 2025

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 45 R37.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT (Details Narrative) - USD ($)	12 Months Ended
LICENSE AGREEMENT (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
LICENSE AGREEMENT
Minimum Royalty Payment	$ 50,000	$ 50,000
Royalty percentage on dental products	10.00%
Royalty percentage on other licensed products	5.00%

XML 46 R38.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accrued expenses - related parties	$ 1,439,000	$ 1,129,000
Sole Officer [Member]
Accrued expenses - related parties	362,000
Chairman [Member]
Accrued expenses - related parties	996,000
Board of Director [Member]
Accrued expenses - related parties	$ 81,000

XML 47 R39.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jan. 26, 2023	Dec. 31, 2022	Dec. 31, 2021
Payment in cash for repayment of note		$ 40,000	$ 0
Subsequent Event [Member]
Strike price per share	$ 0.003
Payment in cash for repayment of note	$ 10,000
Remaining balance of note	$ 20,000
Payment in cash for repayment date	Mar. 22, 2023

XML 48 mhtx_10k_htm.xml IDEA: XBRL DOCUMENT 0001099132 2022-01-01 2022-12-31 0001099132 us-gaap:SubsequentEventMember 2023-01-01 2023-01-26 0001099132 us-gaap:SubsequentEventMember 2023-01-26 0001099132 mhtx:BoardOfDirectorMember 2022-12-31 0001099132 mhtx:ChairmanMember 2022-12-31 0001099132 mhtx:SoleOfficerMember 2022-12-31 0001099132 us-gaap:StockOptionMember 2021-03-22 0001099132 us-gaap:StockOptionMember 2021-03-01 2021-03-22 0001099132 mhtx:ClassCPreferredStockMember 2022-01-01 2022-12-31 0001099132 mhtx:ClassBPreferredStockMember 2022-01-01 2022-12-31 0001099132 mhtx:ClassAPreferredStockMember 2022-01-01 2022-12-31 0001099132 mhtx:CoversionAgreementMember mhtx:HolderMember mhtx:ClassDPreferredStockMember 2022-01-01 2022-12-31 0001099132 mhtx:CoversionAgreementMember mhtx:HolderMember mhtx:ClassDPreferredStockMember 2013-11-01 2013-11-05 0001099132 us-gaap:StockOptionMember 2022-12-31 0001099132 mhtx:UndesignatedBlankCheckMember 2021-12-31 0001099132 mhtx:UndesignatedBlankCheckMember 2022-12-31 0001099132 mhtx:ClassAPreferredStockMember 2022-12-31 0001099132 mhtx:ClassAPreferredStockMember 2021-12-31 0001099132 mhtx:ClassBPreferredStockMember 2022-12-31 0001099132 mhtx:ClassCPreferredStockMember 2021-12-31 0001099132 mhtx:ClassCPreferredStockMember 2022-12-31 0001099132 mhtx:ClassBPreferredStockMember 2021-12-31 0001099132 mhtx:CoversionAgreementMember mhtx:HolderMember mhtx:ClassDPreferredStockMember 2013-11-05 0001099132 mhtx:ExercisePriceRangeSixMember 2022-01-01 2022-12-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2022-01-01 2022-12-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2022-01-01 2022-12-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2022-01-01 2022-12-31 0001099132 mhtx:ExercisePriceRangeSixMember 2022-12-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2022-12-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2022-12-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2022-12-31 0001099132 mhtx:RelatedPartyMember 2022-01-01 2022-12-31 0001099132 mhtx:IndividualsMember 2022-01-01 2022-12-31 0001099132 mhtx:IndividualsMember 2021-01-01 2021-12-31 0001099132 mhtx:RelatedPartyMember 2021-01-01 2021-12-31 0001099132 mhtx:NotesPayableOtherPayablesOneMember 2022-09-01 2022-09-30 0001099132 us-gaap:NotesPayableOtherPayablesMember 2022-09-30 0001099132 us-gaap:NotesPayableOtherPayablesMember 2022-09-01 2022-09-30 0001099132 mhtx:IndividualsMember 2019-10-01 2019-10-17 0001099132 mhtx:RelatedPartyMember 2019-10-01 2019-10-17 0001099132 mhtx:InTwoThousandNineMember mhtx:PatentLicenseAgreementMember mhtx:LosAlamosNationalSecurityLLCMember 2009-01-01 2009-12-31 0001099132 srt:MaximumMember 2022-01-01 2022-12-31 0001099132 srt:MinimumMember 2022-01-01 2022-12-31 0001099132 mhtx:InTwoThousandEightMember mhtx:MetallicumIncMember 2008-06-01 2008-06-30 0001099132 2018-01-01 2018-12-31 0001099132 2020-05-01 2020-05-31 0001099132 2019-01-01 2019-12-31 0001099132 mhtx:SignificantUnobservableInputsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001099132 mhtx:SignificantUnobservableInputsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001099132 mhtx:ImagionBiosystemsIncMember 2022-12-31 0001099132 mhtx:PatentLicenseAgreementMember mhtx:LosAlamosNationalSecurityLLCMember 2009-01-01 2009-01-31 0001099132 mhtx:InTwoThousandEightMember mhtx:MetallicumIncMember 2008-06-01 2008-06-12 0001099132 us-gaap:RetainedEarningsMember 2022-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001099132 us-gaap:CommonStockMember 2022-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2022-12-31 0001099132 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001099132 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2022-01-01 2022-12-31 0001099132 us-gaap:RetainedEarningsMember 2021-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001099132 us-gaap:CommonStockMember 2021-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-12-31 0001099132 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001099132 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2021-01-01 2021-12-31 0001099132 2020-12-31 0001099132 us-gaap:RetainedEarningsMember 2020-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001099132 us-gaap:CommonStockMember 2020-12-31 0001099132 mhtx:PreferredStockSeriesBMember 2020-12-31 0001099132 2021-01-01 2021-12-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2022-12-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassDConvertibleMandatoryRedeemablePreferredStockMember 2022-12-31 0001099132 mhtx:ClassDConvertibleMandatoryRedeemablePreferredStockMember 2021-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2022-12-31 0001099132 mhtx:SeriesBConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:SeriesBConvertiblePreferredStockMember 2022-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2021-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2022-12-31 0001099132 2021-12-31 0001099132 2022-12-31 0001099132 2023-04-07 0001099132 2022-06-30 iso4217:USD shares iso4217:USD shares pure 0001099132 false --12-31 FY 2022

0.001

950000000

559281064

105761

250000

14000

182525

49999

105761

49999

105761

49999

0 0

300000

An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

2022-10-17

P0Y P6Y21D

0.00

0.04

0 0 0 0

26500000

0 0 0

105761

49999

182525

250000

14000

26500000

0.001

100

0.001

0.1 0.1

0.21

10-K true 2022-12-31 false MANHATTAN SCIENTIFICS, INC. DE 000-28411 85-0460639 244 Fifth Ave Suite 2341 New York NY NY 10001 212 541-2405 Common Stock, $0.001 par value No No Yes Yes Non-accelerated Filer true false false 4726599 559281064 3627 Sadler, Gibb & Associates, LLC Draper, UT

175000

232000

14000

15000

300000

189000

547000

839000

2901000

1000

4000

2000

1031000

3454000

119000

102000

1439000

1129000

110000

130000

1668000

1361000

1668000

1361000

105761

1058000

0.001

182525

250000

49999

14000

950000000

559281064

559000

68996000

-71250000

-68520000

-1695000

1035000

1031000

3454000

50000

718000

727000

11000

10000

729000

737000

-679000

-687000

-2030000

-2974000

-48000

21000

26000

-2051000

-2952000

-2730000

-3639000

559281064 559281064 -0.00 -0.01

49999

559281064

559000

68996000

-64881000

4674000

-3639000

49999

559281064

559000

68996000

-68520000

1035000

-2730000

49999

559281064

559000

68996000

-71250000

-1695000

-2730000

-3639000

3000

2000

-2030000

-2974000

20000

26000

-48000

-1000

3000

17000

-105000

310000

276000

-349000

-421000

32000

300000

332000

300000

40000

-40000

-57000

-121000

232000

353000

175000

232000

NOTE 1 – BASIS OF PRESENTATION Manhattan Scientifics, Inc., a Delaware corporation (formerly Grand Enterprises, Inc) (“Grand”) was established on July 31, 1992 and has a wholly-owned subsidiary: Metallicum, Inc. (“Metallicum”). On June 12, 2008, the Company acquired Metallicum, Inc, for 15,000,000 shares of Company’s common stock, Manhattan Scientifics, Inc., operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nano-technologies and nano-medicine. In this capacity, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. The Company has a long standing relationship with Los Alamos Laboratories in New Mexico. During 2008, the Company refocused its efforts from the development of its fuel cell technologies to its current focus on the development of nanomaterials through the acquisition of Metallicum. Metallicum is a nanotechnology start-up company located in Colorado. Metallicum Inc. has focused on the development and manufacture of nanostructured metals for medical implants and other applications. Metallicum intends to establish manufacturing partner relationships with major Fortune 500 metals companies and strategic partnering with significant customers in the medical device & prosthetics industries as well as in auto, truck, & aircraft manufacturing industries. Metallicum’s initial products include nanostructured bulk metals and alloys in the form of rod, bar, wire and foil. The Company conducts its operations primarily in the United States. Manhattan Scientifics purchased Metallicum to acquire its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registrable under copyright or similar laws. In January 2009, the Company entered into a patent license agreement with Los Alamos National Security, LLC for the exclusive licensing use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. Pursuant to such agreement the Company provided a non-refundable fee and 2,000,000 shares of common stock. Additionally, the Company is required to pay an annual license fee which started in February 2010 and royalties on future net sales. In September 2009, the Company entered into a technology transfer agreement with Carpenter Technologies Corporation (“Carpenter”). Wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive technology transfer agreement from Manhattan Scientifics and the Los Alamos National Laboratory. The proprietary process will enable super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums. On February 11, 2015, the Company entered into a Settlement Agreement and Mutual General Releases (the "Settlement Agreement") with Carpenter Technology Corporation related to the agreement discussed in Note 7, pursuant to which the parties settled and released each other from any and all liabilities and claims related to the Carpenter Agreements. On November 17, 2016, Senior Scientific merged with and into Imagion Biosystems, Inc., a Nevada corporation (“Imagion”). Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On June 30, 2017, Imagion completed an IPO and listing on the Australian Stock Exchange (ASX). As of December 31, 2022 , the Company owns 51,566,508 shares (1,000,000 restricted shares related to issued promissory notes interest) of Imagion, resulting in a noncontrolling interest of approximately 5% of Imagion’s issued and outstanding common stock. The Company elected to record the investment at fair value. Manhattan Scientifics success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.

15000000

2000000

51566508 1000000 0.05

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS BASIS OF CONSOLIDATION: The consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated. GOING CONCERN: As of December 31, 2022, the Company has an accumulated deficit of 71,250,000 and negative working capital of $1,479,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing these financial statement. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts. USE OF ESTIMATES: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization. CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments purchased with an original maturity of year or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows. CASH CONCENTRATION: The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of December 31, 2022, we had cash balances of $-0- exceeding the federally insured limits. PROPERTY AND EQUIPMENT: Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.INTANGIBLE ASSETS: License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of 1the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors. DUE FROM THE SALE OF ASSETS: Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. During May 2022 and 2021, the Company received $300,000 and $300,000 respectively and reduced the due from the sale of assets to the balance of $0. As of December 31, 2022, the Company received the full amount from the sale of assets. MARKETABLE SECURITIES: The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the year ended December 31, 2022, no allowance was recorded for credit losses.REVENUE RECOGNITION: The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. The revenue was generated was from minimum royalty payments from the license agreement. FAIR VALUE MEASUREMENTS: The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets;Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash and cash equivalents (consisting of money market funds), short-term investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including prepaid expenses, accounts payable, accrued expenses and notes payables approximated fair value as of December 31, 2022 and December 31, 2021 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of December 31, 2022, the Company holds 51,566,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss on fair value adjustment of investments. Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 and 2021, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements was being amortized over the period of its estimated benefit period of 10 years. The license is fully amortized. Our ability to compete depends in part on the protection of and our ability to defend our proprietary technology and on the goodwill associated with our trade names, service marks and other proprietary rights. However, we do not know if current laws will provide us with sufficient enough protection that others will not develop technologies similar or superior to ours, or that third parties will not copy or otherwise obtain or use our technologies without our authorization. The success of our business will depend, in part, to identify technology, obtain patents, protect and enforce patents once issued and operate without infringing on the proprietary rights of others. Our success will also depend on our ability to maintain exclusive rights to trade secrets and proprietary technology we own are currently developing and will develop. We can give no assurance that any issued patents will provide us with competitive advantages or will not be challenged by others, or that the patents of others will not restrict our ability to conduct business. In addition, we rely on certain technology licensed with a perpetual term from the Los Alamos National Laboratory and may be required to license additional technologies in the future. We do not know if these third-party licenses will be available or will continue to be available to us on acceptable commercial terms or at all. The inability to enter into and maintain any of these licenses could have a material adverse effect on our business, financial condition or results of our operations. Policing unauthorized use of our proprietary technology and other intellectual property rights could entail significant expense. In addition, we do not know if third parties will bring claims of copyright or trademark infringement against us or claim that our use of certain technologies violates a patent or other intellectual property. Any claims of infringement, with or without merit, could be time consuming and expensive to defend, result in costly litigation, divert management attention, require us to enter into costly royalty or licensing arrangements or prevent us from using important technologies or methods, any of which could have a material adverse effect on our business, financial condition or results of our operations. LEASES The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease.INCOME TAXES The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits. BASIC AND DILUTED EARNINGS (LOSS) PER SHARE In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2022 and 2021, 26,655,760 and 26,655,760, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the year ended December 31, 2021. The following table shows the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">The Years Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,730,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,639,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>STOCK BASED COMPENSATION The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50. RECENT ACCOUNTING PRONOUNCEMENTS In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., and its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

As of December 31, 2022, the Company has an accumulated deficit of 71,250,000 and negative working capital of $1,479,000. Because of these conditions, the Company will require additional working capital to develop business operations. The Company intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. These factors raise substantial doubt about the Company’s ability to continue within one year from the date of filing these financial statement. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The ability to continue as a going concern is dependent on out generating cash from the sale of our common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plan includes selling our equity securities and/or obtaining debt financing to fund our capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

-71250000

1479000

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

The Company considers all highly liquid investments purchased with an original maturity of year or less at the time of purchase to be cash equivalents for the purposes of the statement of cash flows.

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of December 31, 2022, we had cash balances of $-0- exceeding the federally insured limits.

250000

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets, the useful lives range between 3-10 years, using the straight-line method for financial statement purposes.

P3Y

P10Y

License Agreements In 2008, the Company obtained licenses to the rights of certain patents regarding nanostructured materials developed by another company as a result of 1the acquisition of Metallicum. The purchase price paid for these licenses was $305,000, which represented its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Under the terms of the agreement, the Company may be required to pay royalties, as defined, to the licensors. In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The purchase price paid for this license agreement was $33,000 based on the fair market value of 2,000,000 shares of common stock issued. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. At December 31, 2022 and December 31, 2021, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

305000

P10Y

2000000

10000 Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use. Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss. During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. During May 2022 and 2021, the Company received $300,000 and $300,000 respectively and reduced the due from the sale of assets to the balance of $0. As of December 31, 2022, the Company received the full amount from the sale of assets. 1200000 1200000

300000

The Company considers securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within other income (loss). The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other income (loss). For the year ended December 31, 2022, no allowance was recorded for credit losses.

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation. Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable. The revenue was generated was from minimum royalty payments from the license agreement.

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 — Quoted prices for identical assets and liabilities in active markets;Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andLevel 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company designates cash and cash equivalents (consisting of money market funds), short-term investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis. Fair value of financial instruments: The carrying amounts of financial instruments, including prepaid expenses, accounts payable, accrued expenses and notes payables approximated fair value as of December 31, 2022 and December 31, 2021 because of the relative short term nature of these instruments. During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of December 31, 2022, the Company holds 51,566,508 shares of Imagion and is reported under fair value method under ASC 320. Any change in the value is reported on the income statement as an unrealized gain or loss on fair value adjustment of investments. Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2022 and 2021, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

51566508 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total fair value at December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Total fair value at December 31, 2021</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Quoted prices in active markets for identical assets (Level1)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant other observable inputs (Level 2)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Significant unobservable inputs (Level 3)</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Investment in equity securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

839000

2901000

In June 2008, we acquired Metallicum and its licensed rights to patented technology. The technology is comprised of three US Patents (US Patent numbers 7152448, 6197129 and 6399215) for which Metallicum (subsequently, Manhattan) had been assigned an exclusive license rights by Los Alamos National Security LLC (LANL). Under the license rights, Metallicum had all rights, title and interest throughout the world in and to any and all inventions, original works of authorship, developments, concepts, know-how, and improvements on the patents or trade secrets whether or not patentable or registerable under copyright or similar laws. The purchase price paid for these licenses was $305,000, which represents its fair value. The Company obtained an exclusive license on two patents and a non-exclusive license on the third patent. The value attributable to license agreements was being amortized over the period of its estimated benefit period of 10 years. The license is fully amortized. Our ability to compete depends in part on the protection of and our ability to defend our proprietary technology and on the goodwill associated with our trade names, service marks and other proprietary rights. However, we do not know if current laws will provide us with sufficient enough protection that others will not develop technologies similar or superior to ours, or that third parties will not copy or otherwise obtain or use our technologies without our authorization. The success of our business will depend, in part, to identify technology, obtain patents, protect and enforce patents once issued and operate without infringing on the proprietary rights of others. Our success will also depend on our ability to maintain exclusive rights to trade secrets and proprietary technology we own are currently developing and will develop. We can give no assurance that any issued patents will provide us with competitive advantages or will not be challenged by others, or that the patents of others will not restrict our ability to conduct business. In addition, we rely on certain technology licensed with a perpetual term from the Los Alamos National Laboratory and may be required to license additional technologies in the future. We do not know if these third-party licenses will be available or will continue to be available to us on acceptable commercial terms or at all. The inability to enter into and maintain any of these licenses could have a material adverse effect on our business, financial condition or results of our operations. Policing unauthorized use of our proprietary technology and other intellectual property rights could entail significant expense. In addition, we do not know if third parties will bring claims of copyright or trademark infringement against us or claim that our use of certain technologies violates a patent or other intellectual property. Any claims of infringement, with or without merit, could be time consuming and expensive to defend, result in costly litigation, divert management attention, require us to enter into costly royalty or licensing arrangements or prevent us from using important technologies or methods, any of which could have a material adverse effect on our business, financial condition or results of our operations.

The Company leases a facility with terms of month to month for its headquarters. The Company adopted ASC 842 on January 1, 2019 and has evaluated that has no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore, is not required to capitalize the lease.

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations. ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net income (loss) per share excludes the dilutive effect of stock options or warrants and convertible notes Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2022 and 2021, 26,655,760 and 26,655,760, respectively, dilutive shares were excluded from the calculation of diluted earnings (loss) per common share, as the effect of these shares on earnings per share would have been anti-dilutive; however, dilutive shares were included from the calculation of diluted income common shares for the year ended December 31, 2021. The following table shows the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2022 and 2021: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">The Years Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Numerator:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,730,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,639,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Denominator:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average basic shares outstanding</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of dilutive securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted-average diluted shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">559,281,064</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Basic earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted earnings (loss) per share</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.01</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>

26655760

-2730000

-3639000

559281064

-0.00

-0.01

-0.00

-0.01

The Company accounts for stock-based compensation based on the fair value of all option grants or stock issuances made to employees or directors on or after its implementation date (the beginning of fiscal 2006), as well as, a portion of the fair value of each option and stock grant made to employees or directors prior to the implementation date that represents the unvested portion of these share-based awards as of such implementation date, to be recognized as an expense, as codified in ASC 718. The Company calculates stock option-based compensation by estimating the fair value of each option as of its date of grant using the Black-Scholes option pricing model. These amounts are expensed over the respective vesting periods of each award using the straight-line attribution method. Compensation expense is recognized only for those awards that are expected to vest, and as such, amounts have been reduced by estimated forfeitures. The Company has historically issued stock options and vested and non-vested stock grants to employees and outside directors whose only condition for vesting has been continued employment or service during the related vesting or restriction period. The estimated fair value of grants of stock options and warrants to nonemployees of the Company is charged to expense, if applicable, in the financial statements. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505-50. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. This amendment is effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements.

NOTE 3 – INVESTMENT IN IMAGION BIOSYSTEMS As of December 31, 2022, the Company owns 51,566,508 shares of Imagion, resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Based upon Imagion’s trading price on December 31, 2022, approximately $0.01 per share, the fair value of the Imagion shares was approximately $839,000. During the year ended December 31, 2021, the Company recorded loss on fair value adjustment on its investment of $2,030,000. Below is reconciliation for the changes to the investment in Imagion for the year ended December 31, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in the unrealized fair value of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,030,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sales of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

51566508 0.01

839000

2030000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,901,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in the unrealized fair value of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,030,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Sales of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">839,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2901000

-2030000

32000

839000

NOTE 4 – NOTES PAYABLE On October 17, 2019, The Company executed two secured notes with a related party for $100,000. The secured notes were due on October 17, 2022. The notes bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 2 million shares of IBX common stock. The amortization of debt discount for the year ended December 31, 2022 and 2021 was $13,334 and $17,000, respectively. On October 17, 2019, the Company executed a secured note with an individual for $50,000. The secured note was due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per shares with 1 million shares of IBX common stock. The amortization of debt discount for the years ended December 31, 2022 and 2021 was $6,666 and $9,000, respectively. On September 30, 2022, the Company made $10,000 repayments and the notes payable balance was reduced to $140,000 from $150,000. On September 30, 2022, the Company made $30,000 repayments and the notes payable balance was reduced to $110,000. Notes payable as of December 31, 2022 were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Discounts on notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable, net of discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

100000

0.10

0.015 2000000

13334

17000

50000

2022-10-17

0.10

0.015 1000000

6666

9000

10000

140000

150000

30000

110000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Discounts on notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable, net of discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 130000 -20000

110000

NOTE 5 – CAPTIAL TRANSACTIONS Preferred Stock The Company has a total of 1,000,000 shares of authorized preferred shares which are segregated into four classes of preferred stock. The Company has 182,525 authorized shares of convertible, redeemable, 10 percent cumulative, Class A, Preferred Stock with $0.001 par value. One Class A, Preferred share is convertible into 50 restricted common shares and will be entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Series A Preferred stock could be converted at the time of the vote. Class A, Preferred Stock is redeemable by the Company at $15 per share. Upon liquidation the holders of Series A Preferred stock will be entitled to be paid out of the assets available for distribution of the corporation an amount equal to $10 per share, before any payment will be made to the common shareholders. As of December 31, 2022 and 2021, no shares of Preferred Stock were issued and outstanding. The Company has 250,000 authorized shares of Class B, Preferred Stock with $0.001 par value. As of December 31, 2022 and 2021, 49,999 and 49,999 shares of Preferred Stock were issued and outstanding, respectively. Class B preferred shares are convertible at a rate of 1 Series B preferred share to 10 common shares. The Company has 14,000 authorized shares of redeemable, convertible, Class C, Preferred Stock with $100 stated value. Class C, Preferred Stock is not entitled to receive dividends unless dividends are paid on common stock. Upon liquidation Class C, Preferred Stock shall be treated as if it were converted to common stock prior to liquidation. Class C, Preferred Stock is convertible at $100 divided by the 10 day average closing price of common stock. The Class C, Preferred Stock is redeemable by the Company at the stated value. As of December 31, 2022 and 2021, no shares of Preferred Stock were issued and outstanding. On November 5, 2013, the Company entered into a Conversion Agreement with Marvin Maslow (the "Holder") pursuant to which the Company agreed to convert $1,057,608 of debt (the "Debt"), including principal and interest, currently owed to Holder into 105,761 shares of Series D Preferred Shares of the Company. The Debt had been outstanding since 2007. The above transactions were approved by the Board of Directors of the Company. The Series D Preferred Stock does not pay dividends and does not have a liquidation preference. The Holder of the Series D Preferred Stock will be entitled to 20 votes for each share of common stock that the Series D Preferred Stock are convertible into. The Series D Preferred Stock has a conversion price of $0.055 (the “Conversion Price”) and a stated value of $10.00 (the “Stated Value”) per share. Each share of Series D Preferred Stock is convertible, at the option of the Holder, into such number of shares of common stock of the Company as determined by dividing Stated Value by the Conversion Price. Holder may only convert the Series D Preferred Stock upon certain Convertible Promissory Notes, whether presently outstanding or to be issued, issued to three accredited investors (the "Note Investors") in accordance with those certain Convertible Note Purchase Agreements between the Company and the Note Investors dated April 3, 2013, have either (i) been converted in full or in part by the Note Investors into shares of common stock of the Company, (ii) the Note Investors have sold or assigned all or a part of their Convertible Promissory Notes to third parties, or (iii) the Note Investors have been paid in full or in part. The Holder will only be permitted to convert such number of Series D Preferred Stock equal to the pro rata amount of the Convertible Promissory Notes converted, assigned or paid. In the event the Note Investors agree in writing that these restrictions may be terminated, then the Holder will be entitled to convert the Series D Preferred Stock at the Holder’s election and the above restrictions will be null and void. Additionally, Holder may not convert the Series D Preferred Stock until the ten day average daily trading volume is greater than $20,000. As of the date of this filing, this has not occurred yet.In the event the Holder terminates its consulting agreement or violates a non-compete covenant, then the Series D Preferred Shares shall be returned to the Company for cancellation and the Company shall be obligated on the Debt. As the Series D Preferred Stock is conditionally redeemable, the Company has recorded the Series D Preferred Stock as mezzanine equity in the accompanying consolidated balance sheet. The Company has 447,804 and 447,804 undesignated blank check preferred stock, $0.001 par value, authorized as of December 31, 2022 and 2021. The preferred shares are to be issued in such series and to have such rights, preferences, and designation as determine by the Board of Directors of the Company. Common Stock The Company has a total of 950,000,000 shares of authorized common shares. As of December 31, 2022 and 2021, 559,281,064 and 559,281,064 shares of common stock were issued and outstanding, respectively. Stock Activity during 2022 and 2021 During the year ended December 31, 2022 and 2021, the Company had not issued common stock. Options On March 22, 2021, the Company entered into a settlement with a third party, which the Company granted 15,000,000 shares of common stock options to purchase 15,000,000 shares of common stock at an exercise price of $0.0154. The options price was based on the closing market price of common stock on October 1, 2020. The Settlement is for the Employment Agreement with a third party, dated January 12, 2015 to which the Company agreed to issued common shares. At December 31, 2022, the 26,500,000 outstanding options had an aggregate intrinsic value of $0. A summary of the Company’s stock option activity and related information is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.84</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.68</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,000,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,000,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.06</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.97</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIESNOTES TO THE CONSOLIDATED FINANCIAL STATEMENTSFOR THE YEAR ENDED DECEMBER 31, 2022 Exercise prices and weighted-average contractual lives of 26,500,000 stock options outstanding as of December 31, 2022 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Options Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Number Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Number Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td style="width:6%;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.50</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.06</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.60</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.14</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.50</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td><td style="white-space: nowrap;"> </td></tr></tbody></table> The fair value for options granted were determined using the Black-Scholes option-pricing model. The Company did not recognize compensation expense during the year ended December 31, 2022.

1000000

182525

0.001

One Class A, Preferred share is convertible into 50 restricted common shares and will be entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Series A Preferred stock could be converted at the time of the vote

Class A, Preferred Stock is redeemable by the Company at $15 per share

Upon liquidation the holders of Series A Preferred stock will be entitled to be paid out of the assets available for distribution of the corporation an amount equal to $10 per share, before any payment will be made to the common shareholders

250000

0.001

49999

Class B preferred shares are convertible at a rate of 1 Series B preferred share to 10 common shares

14000

100

Upon liquidation Class C, Preferred Stock shall be treated as if it were converted to common stock prior to liquidation

Class C, Preferred Stock is convertible at $100 divided by the 10 day average closing price of common stock

1057608

105761

The Holder of the Series D Preferred Stock will be entitled to 20 votes for each share of common stock that the Series D Preferred Stock are convertible into

0.055

10.00

Additionally, Holder may not convert the Series D Preferred Stock until the ten day average daily trading volume is greater than $20,000

447804

0.001

950000000

559281064

15000000

0.0154

26500000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Remaining Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number of Options Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.84</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.68</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,000,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,000,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.06</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.04</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4.97</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">26,500,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

18500000

0.07

P2Y10M2D

18500000

15000000

0.02

P9Y8M4D

15000000

15000

7000000

0.07

-7000000

26500000

0.04

P6Y21D

26500000

15000

26500000

0.04

P4Y11M19D

26500000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Options Outstanding</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Options Exercisable</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Number Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Remaining Contractual Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Number Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td style="width:6%;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.02</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.50</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.06</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.60</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.06</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.14</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.50</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.14</td><td style="white-space: nowrap;"> </td></tr></tbody></table>

15500000

P7Y6M18D

0.02

15500000

0.02

3000000

P2Y6M

0.05

3000000

0.05

5000000

P2Y7M6D

0.06

5000000

0.06

3000000

P1Y6M

0.14

3000000

0.14

NOTE 6 – INCOME TAXES The provision for income taxes on the statements of operations consists of $-0- and $-0- for the years ended December 31, 2022 and 2021, respectively. Deferred tax assets are comprised of the following at December 31: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss carryforward</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,501,350</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,704,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Temporary differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,988,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,988,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,489,350</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,692,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. At December 31, 2022 and 2021, management determined that realization of these benefits is not assured and has provided a valuation allowance for the entire amount of such benefits. At December 31, 2022 and 2021, net operating loss carryforwards were approximately $47,275,000 and $47,275,000, respectively, for federal tax purposes that expire at various dates through 2031 and for state tax purposes expire through 2025. Utilization of net operating loss carryforwards may be subject to substantial annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986, as amended, and similar state regulations. The annual limitation may result in the expiration of substantial net operating loss carryforwards before utilization. For December 31, 2022 and 2021, the provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate (21% in 2021 and 2020) to income taxes as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tax benefit computed at 21%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(737,100</td><td style="width:1%;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">982,530</td><td style="width:1%;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">737,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">982,530</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in carryovers and tax attributes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> -</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax provision</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss carryforward</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,501,350</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,704,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Temporary differences</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,988,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,988,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20,489,350</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,692,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred tax asset, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

13501350

12704000

6988000

-20489350 -19692000

47275000

through 2031 through 2025

0.21

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tax benefit computed at 21%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(737,100</td><td style="width:1%;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">982,530</td><td style="width:1%;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">737,100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">982,530</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in carryovers and tax attributes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> -</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Income tax provision</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

-737100 -982530

737100

982530

0 0

NOTE 7 – LICENSE AGREEMENT On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the years ended December 31, 2022 and 2021, the Company received $50,000 and $50,000, respectively, as a minimum royalty payment. 0.10 0.05

50000

NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

NOTE 9 – RELATED PARTY TRANSACTIONS As of December 31, 2022 and December 31, 2021, the Company had accrued expenses to related parties of approximately $1,439,000 and $1,129,000. As of December 31, 2022, the amounts are due to the Company’s sole officer for compensation $362,000 and the chairman of the board for compensation of $996,000 and the members of the board of directors of $81,000.

1439000

1129000

362000

996000

81000

NOTE 10 – SUBSEQUENT EVENTS In January 2023, the Company signed an agreement with one of its noteholders to pay one million IBX shares with a strike price of $0.003 per share USD, the transfer was made on January 26, 2023, in addition to $10,000 in cash for repayment on March 22, 2023. The remaining balance of $20,000 will be paid later.

0.003

10000

2023-03-22 20000 EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 92 212 1 false 42 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://mahatten.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://mahatten.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mahatten.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mahatten.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION Sheet http://mahatten.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Notes 8 false false R9.htm 000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS Sheet http://mahatten.com/role/InvestmentInImagionBiosystems INVESTMENT IN IMAGION BIOSYSTEMS Notes 9 false false R10.htm 000010 - Disclosure - NOTES PAYABLE Notes http://mahatten.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 000011 - Disclosure - CAPITAL TRANSACTIONS Sheet http://mahatten.com/role/CapitalTransactions CAPITAL TRANSACTIONS Notes 11 false false R12.htm 000012 - Disclosure - INCOME TAXES Sheet http://mahatten.com/role/IncomeTaxes INCOME TAXES Notes 12 false false R13.htm 000013 - Disclosure - LICENSE AGREEMENT Sheet http://mahatten.com/role/LicenseAgreement LICENSE AGREEMENT Notes 13 false false R14.htm 000014 - Disclosure - COMMITMENTS AND CONTIGENCIES Sheet http://mahatten.com/role/CommitmentsAndContigencies COMMITMENTS AND CONTIGENCIES Notes 14 false false R15.htm 000015 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://mahatten.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 000016 - Disclosure - SUBSEQUENT EVENTS Sheet http://mahatten.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Policies 17 false false R18.htm 000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Tables http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters 18 false false R19.htm 000019 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Sheet http://mahatten.com/role/InvestmentInImagionBiosystemsTables INVESTMENT IN IMAGION BIOSYSTEMS (Tables) Tables http://mahatten.com/role/InvestmentInImagionBiosystems 19 false false R20.htm 000020 - Disclosure - NOTES PAYABLE (Tables) Notes http://mahatten.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://mahatten.com/role/NotesPayable 20 false false R21.htm 000021 - Disclosure - CAPITAL TRANSACTIONS (Tables) Sheet http://mahatten.com/role/CapitalTransactionsTables CAPITAL TRANSACTIONS (Tables) Tables http://mahatten.com/role/CapitalTransactions 21 false false R22.htm 000022 - Disclosure - INCOME TAXES (Tables) Sheet http://mahatten.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://mahatten.com/role/IncomeTaxes 22 false false R23.htm 000023 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://mahatten.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://mahatten.com/role/BasisOfPresentation 23 false false R24.htm 000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 24 false false R25.htm 000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 25 false false R26.htm 000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Sheet http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Details http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 26 false false R27.htm 000027 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details) Sheet http://mahatten.com/role/InvestmentInImagionBiosystemsDetails INVESTMENT IN IMAGION BIOSYSTEMS (Details) Details http://mahatten.com/role/InvestmentInImagionBiosystemsTables 27 false false R28.htm 000028 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Sheet http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative) Details http://mahatten.com/role/InvestmentInImagionBiosystemsTables 28 false false R29.htm 000029 - Disclosure - NOTES PAYABLE (Details) Notes http://mahatten.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://mahatten.com/role/NotesPayableTables 29 false false R30.htm 000030 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://mahatten.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://mahatten.com/role/NotesPayableTables 30 false false R31.htm 000031 - Disclosure - CAPITAL TRANSACTIONS (Details) Sheet http://mahatten.com/role/CapitalTransactionsDetails CAPITAL TRANSACTIONS (Details) Details http://mahatten.com/role/CapitalTransactionsTables 31 false false R32.htm 000032 - Disclosure - CAPITAL TRANSACTIONS (Details 1) Sheet http://mahatten.com/role/CapitalTransactionsDetails1 CAPITAL TRANSACTIONS (Details 1) Details http://mahatten.com/role/CapitalTransactionsTables 32 false false R33.htm 000033 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative) Sheet http://mahatten.com/role/CapitalTransactionsDetailsNarrative CAPITAL TRANSACTIONS (Details Narrative) Details http://mahatten.com/role/CapitalTransactionsTables 33 false false R34.htm 000034 - Disclosure - INCOME TAXES (Details) Sheet http://mahatten.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://mahatten.com/role/IncomeTaxesTables 34 false false R35.htm 000035 - Disclosure - INCOME TAXES (Details 1) Sheet http://mahatten.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://mahatten.com/role/IncomeTaxesTables 35 false false R36.htm 000036 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://mahatten.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://mahatten.com/role/IncomeTaxesTables 36 false false R37.htm 000037 - Disclosure - LICENSE AGREEMENT (Details Narrative) Sheet http://mahatten.com/role/LicenseAgreementDetailsNarrative LICENSE AGREEMENT (Details Narrative) Details http://mahatten.com/role/LicenseAgreement 37 false false R38.htm 000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://mahatten.com/role/RelatedPartyTransactions 38 false false R39.htm 000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://mahatten.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://mahatten.com/role/SubsequentEvents 39 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mhtx_10k.htm 1 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 73 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, mhtx:AggregateIntrinsicValueExpired, mhtx:AggregateIntrinsicValueGranted, mhtx:CumulativePreferredStockInterestRate, mhtx:EffectOfDilutiveSecurities, mhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedExercisableNumber, mhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber, mhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber, mhtx:WeightedAverageLifeGranted, mhtx:WeightedAverageLifeOutstandingEndingBalance, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentMaturityDate, us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate, us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement, us-gaap:Investments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockRedemptionPricePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProceedsFromSaleOfPropertyHeldForSale, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice, us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice, us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice, us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice, us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised - mhtx_10k.htm 1 mhtx_10k.htm mhtx-20221231.xsd mhtx-20221231_cal.xml mhtx-20221231_def.xml mhtx-20221231_lab.xml mhtx-20221231_pre.xml mhtx_311.htm mhtx_321.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mhtx_10k.htm": { "axisCustom": 0, "axisStandard": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 358, "http://xbrl.sec.gov/dei/2022": 35 }, "contextCount": 92, "dts": { "calculationLink": { "local": [ "mhtx-20221231_cal.xml" ] }, "definitionLink": { "local": [ "mhtx-20221231_def.xml" ] }, "inline": { "local": [ "mhtx_10k.htm" ] }, "labelLink": { "local": [ "mhtx-20221231_lab.xml" ] }, "presentationLink": { "local": [ "mhtx-20221231_pre.xml" ] }, "schema": { "local": [ "mhtx-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 318, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 59, "http://mahatten.com/20221231": 13, "http://xbrl.sec.gov/dei/2022": 5, "total": 77 }, "keyCustom": 47, "keyStandard": 165, "memberCustom": 31, "memberStandard": 11, "nsprefix": "mhtx", "nsuri": "http://mahatten.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mahatten.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - NOTES PAYABLE", "menuCat": "Notes", "order": "10", "role": "http://mahatten.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - CAPITAL TRANSACTIONS", "menuCat": "Notes", "order": "11", "role": "http://mahatten.com/role/CapitalTransactions", "shortName": "CAPITAL TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "12", "role": "http://mahatten.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - LICENSE AGREEMENT", "menuCat": "Notes", "order": "13", "role": "http://mahatten.com/role/LicenseAgreement", "shortName": "LICENSE AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - COMMITMENTS AND CONTIGENCIES", "menuCat": "Notes", "order": "14", "role": "http://mahatten.com/role/CommitmentsAndContigencies", "shortName": "COMMITMENTS AND CONTIGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "15", "role": "http://mahatten.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "16", "role": "http://mahatten.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)", "menuCat": "Policies", "order": "17", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)", "menuCat": "Tables", "order": "18", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Tables)", "menuCat": "Tables", "order": "19", "role": "http://mahatten.com/role/InvestmentInImagionBiosystemsTables", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://mahatten.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfDebtDiscount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - NOTES PAYABLE (Tables)", "menuCat": "Tables", "order": "20", "role": "http://mahatten.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "mhtx:ScheduleOfDebtDiscount", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - CAPITAL TRANSACTIONS (Tables)", "menuCat": "Tables", "order": "21", "role": "http://mahatten.com/role/CapitalTransactionsTables", "shortName": "CAPITAL TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://mahatten.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ImagionBiosystemsIncMember", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ImagionBiosystemsIncMember", "decimals": "INF", "lang": null, "name": "mhtx:IssuedAndOutstandingSharesNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)", "menuCat": "Details", "order": "24", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_SignificantOtherObservableInputsMember_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1)", "menuCat": "Details", "order": "25", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details)", "menuCat": "Details", "order": "27", "role": "http://mahatten.com/role/InvestmentInImagionBiosystemsDetails", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ImagionBiosystemsIncMember", "decimals": "0", "first": true, "lang": null, "name": "mhtx:CommonStockOwnedShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ImagionBiosystemsIncMember", "decimals": "INF", "lang": null, "name": "mhtx:TradingPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfDebtDiscount", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:NotesPayableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - NOTES PAYABLE (Details)", "menuCat": "Details", "order": "29", "role": "http://mahatten.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ScheduleOfDebtDiscount", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:NotesPayableGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ClassAConvertiblePreferredStockMember", "decimals": "0", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://mahatten.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-09-01to2022-09-30_us-gaap_NotesPayableOtherPayablesMember", "decimals": "0", "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - CAPITAL TRANSACTIONS (Details)", "menuCat": "Details", "order": "31", "role": "http://mahatten.com/role/CapitalTransactionsDetails", "shortName": "CAPITAL TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - CAPITAL TRANSACTIONS (Details 1)", "menuCat": "Details", "order": "32", "role": "http://mahatten.com/role/CapitalTransactionsDetails1", "shortName": "CAPITAL TRANSACTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mhtx:ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_ExercisePriceRangeSevenMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - CAPITAL TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "shortName": "CAPITAL TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2021-03-01to2021-03-22_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "mhtx:ExercisablePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "34", "role": "http://mahatten.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:TaxBenefitComputedAt21", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - INCOME TAXES (Details 1)", "menuCat": "Details", "order": "35", "role": "http://mahatten.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "mhtx:TaxBenefitComputedAt21", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://mahatten.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "mhtx:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - LICENSE AGREEMENT (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://mahatten.com/role/LicenseAgreementDetailsNarrative", "shortName": "LICENSE AGREEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "mhtx:LicenseAgreementTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2022-12-31_mhtx_SoleOfficerMember", "decimals": "0", "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfSubsequentEventsTextBlock", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2023-01-26_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://mahatten.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2020-12-31_mhtx_PreferredStockSeriesBMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "5", "role": "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "AsOf2020-12-31_mhtx_PreferredStockSeriesBMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://mahatten.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS", "menuCat": "Notes", "order": "8", "role": "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - INVESTMENT IN IMAGION BIOSYSTEMS", "menuCat": "Notes", "order": "9", "role": "http://mahatten.com/role/InvestmentInImagionBiosystems", "shortName": "INVESTMENT IN IMAGION BIOSYSTEMS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mhtx_10k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://mahatten.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "mhtx_AdjustedAssetValuation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Adjusted asset valuation" } } }, "localname": "AdjustedAssetValuation", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "mhtx_AggregateIntrinsicValueExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Expired" } } }, "localname": "AggregateIntrinsicValueExpired", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_AggregateIntrinsicValueGranted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, Granted" } } }, "localname": "AggregateIntrinsicValueGranted", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_AnnualLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Annual license fee" } } }, "localname": "AnnualLicenseFee", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_BasicAndDilutedIncomeLossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted loss per common share (Basic and Diluted)" } } }, "localname": "BasicAndDilutedIncomeLossPerCommonShareBasicAndDiluted", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "mhtx_BoardOfDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Director [Member]" } } }, "localname": "BoardOfDirectorMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares acquired" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssue", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_CashConcentration": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH CONCENTRATION" } } }, "localname": "CashConcentration", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_ChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chairman [Member]" } } }, "localname": "ChairmanMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ChangeInCarryoversAndTaxAttributes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in carryovers and tax attributes" } } }, "localname": "ChangeInCarryoversAndTaxAttributes", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "mhtx_ChangeInUnrealizedGainInInvestment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in unrealized gain in investment" } } }, "localname": "ChangeInUnrealizedGainInInvestment", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_ClassAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Convertible Preferred Stock [Member]" } } }, "localname": "ClassAConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Preferred Stock [Member]" } } }, "localname": "ClassAPreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ClassBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Convertible Preferred Stock [Member]" } } }, "localname": "ClassBConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Preferred Stock [Member]" } } }, "localname": "ClassBPreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ClassCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class C Preferred Stock [Member]" } } }, "localname": "ClassCPreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ClassCRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class C Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "ClassCRedeemableConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassDConvertibleMandatoryRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class D Convertible Mandatory Redeemable Preferred Stock [Member]" } } }, "localname": "ClassDConvertibleMandatoryRedeemablePreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "mhtx_ClassDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class D Preferred Stock [Member]" } } }, "localname": "ClassDPreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_CommonStockOwnedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Common stock owned shares]", "verboseLabel": "Common stock owned shares" } } }, "localname": "CommonStockOwnedShare", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_CommonStockOwnedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock owned shares", "verboseLabel": "Common stock owned shares" } } }, "localname": "CommonStockOwnedShares", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_CoversionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Coversion Agreement [Member]" } } }, "localname": "CoversionAgreementMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_CumulativePreferredStockInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative preferred stock interest rate" } } }, "localname": "CumulativePreferredStockInterestRate", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_DueFromTheSaleOfAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DUE FROM THE SALE OF ASSETS" } } }, "localname": "DueFromTheSaleOfAssetsPolicyTextBlock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_EarningsPerSharesBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "EarningsPerSharesBasicAndDilutedAbstract", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "stringItemType" }, "mhtx_EffectOfDilutiveSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect of dilutive securities" } } }, "localname": "EffectOfDilutiveSecurities", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" }, "mhtx_ExercisablePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable price" } } }, "localname": "ExercisablePrice", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mhtx_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.02 [Member]" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.14 [Member]" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.06 [Member]" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price 0.05 [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "mhtx_ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise prices and weighted-average contractual lives of stock options outstanding" } } }, "localname": "ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "mhtx_FederalTaxPurposesExpire": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal net operating loss carryforwards expiration date" } } }, "localname": "FederalTaxPurposesExpire", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "mhtx_HolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Holder [Member]" } } }, "localname": "HolderMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_ImagionBiosystemsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Imagion Biosystems, Inc. [Member]" } } }, "localname": "ImagionBiosystemsIncMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_InTwoThousandEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In 2008 [Member]" } } }, "localname": "InTwoThousandEightMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_InTwoThousandNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In 2009 [Member]" } } }, "localname": "InTwoThousandNineMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_IndividualsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Individuals [Member]" } } }, "localname": "IndividualsMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_IssuedAndOutstandingSharesNoncontrollingInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued and outstanding shares noncontrolling interest" } } }, "localname": "IssuedAndOutstandingSharesNoncontrollingInterest", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_LessDiscountsOnNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less: Discounts on notes payable" } } }, "localname": "LessDiscountsOnNotesPayable", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_LessValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less valuation allowance" } } }, "localname": "LessValuationAllowance", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[LICENSE AGREEMENT]", "verboseLabel": "LICENSE AGREEMENT" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/LicenseAgreement" ], "xbrltype": "textBlockItemType" }, "mhtx_LosAlamosNationalSecurityLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Los Alamos National Security LLC [Member]", "verboseLabel": "Los Alamos National Security LLC [Member]" } } }, "localname": "LosAlamosNationalSecurityLLCMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_MarketableSecuritiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MARKETABLE SECURITIES" } } }, "localname": "MarketableSecuritiesPolicyTextBlock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "mhtx_MetallicumIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Metallicum, Inc [Member]" } } }, "localname": "MetallicumIncMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_NotesPayableGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Notes payable" } } }, "localname": "NotesPayableGross", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "mhtx_NotesPayableOtherPayablesOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 1 [Member]" } } }, "localname": "NotesPayableOtherPayablesOneMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_NumberOfOptionsExercisableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercisable" } } }, "localname": "NumberOfOptionsExercisableAbstract", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "mhtx_OptionToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option to purchase common stock" } } }, "localname": "OptionToPurchaseCommonStock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "mhtx_PatentLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent license agreement [Member]", "verboseLabel": "Patent license agreement [Member]" } } }, "localname": "PatentLicenseAgreementMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_PaymentInCashForRepaymentDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payment in cash for repayment date" } } }, "localname": "PaymentInCashForRepaymentDate", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "mhtx_PreferredStockLiquidationPreferenceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred stock liquidation preference description" } } }, "localname": "PreferredStockLiquidationPreferenceDescription", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "mhtx_PreferredStockSeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Series B" } } }, "localname": "PreferredStockSeriesBMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "mhtx_PricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Price per share" } } }, "localname": "PricePerShare", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mhtx_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_RemainingBalanceOfNotePayableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Remaining balance of note" } } }, "localname": "RemainingBalanceOfNotePayableAmount", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_RestrictedSharesRelatedToIssuedPromissoryNotesInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted shares related to issued promissory notes interest" } } }, "localname": "RestrictedSharesRelatedToIssuedPromissoryNotesInterest", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_RoyaltyPercentageOnDentalProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty percentage on dental products" } } }, "localname": "RoyaltyPercentageOnDentalProducts", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_RoyaltyPercentageOnOtherLicensedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty percentage on other licensed products" } } }, "localname": "RoyaltyPercentageOnOtherLicensedProducts", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "percentItemType" }, "mhtx_SaleOfAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Sale of asset" } } }, "localname": "SaleOfAsset", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mhtx_ScheduleOfDebtDiscount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of debt discount" } } }, "localname": "ScheduleOfDebtDiscount", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "mhtx_ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value measurement of assets and liabilities" } } }, "localname": "ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables" ], "xbrltype": "textBlockItemType" }, "mhtx_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B convertible preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercisable, Excercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedExercisableNumber", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercisable, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of Options Exercisable, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "mhtx_SharesIssuedInAdvanceForDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued in advance for debt" } } }, "localname": "SharesIssuedInAdvanceForDebt", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mhtx_SignificantOtherObservableInputsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant other observable inputs [Member]" } } }, "localname": "SignificantOtherObservableInputsMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "mhtx_SignificantUnobservableInputsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant unobservable inputs [Member]" } } }, "localname": "SignificantUnobservableInputsMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "mhtx_SoleOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sole Officer [Member]" } } }, "localname": "SoleOfficerMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_StateTaxPurposesExpire": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "State net operating loss carryforwards expiration date" } } }, "localname": "StateTaxPurposesExpire", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "mhtx_TaxBenefitComputedAt21": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tax benefit computed at 21%" } } }, "localname": "TaxBenefitComputedAt21", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "mhtx_TradingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trading price per share" } } }, "localname": "TradingPricePerShare", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mhtx_UndesignatedBlankCheckMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Undesignated blank check [Member]" } } }, "localname": "UndesignatedBlankCheckMember", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mhtx_WeightedAverageExercisePriceExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, exercisable" } } }, "localname": "WeightedAverageExercisePriceExercisable", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "perShareItemType" }, "mhtx_WeightedAverageLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life" } } }, "localname": "WeightedAverageLifeAbstract", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "mhtx_WeightedAverageLifeGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life, Granted" } } }, "localname": "WeightedAverageLifeGranted", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "durationItemType" }, "mhtx_WeightedAverageLifeOutstandingBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life, Outstanding Beginning Balance" } } }, "localname": "WeightedAverageLifeOutstandingBeginningBalance", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "durationItemType" }, "mhtx_WeightedAverageLifeOutstandingEndingBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life, Outstanding Ending Balance" } } }, "localname": "WeightedAverageLifeOutstandingEndingBalance", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "durationItemType" }, "mhtx_WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding (Basic and Diluted)" } } }, "localname": "WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "mhtx_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working capital deficit" } } }, "localname": "WorkingCapital", "nsuri": "http://mahatten.com/20221231", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r202", "r203", "r204", "r205", "r257", "r356", "r379", "r390", "r391", "r407", "r411", "r415", "r444", "r482", "r483", "r484", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r202", "r203", "r204", "r205", "r257", "r356", "r379", "r390", "r391", "r407", "r411", "r415", "r444", "r482", "r483", "r484", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r202", "r203", "r204", "r205", "r249", "r257", "r268", "r269", "r270", "r331", "r356", "r379", "r390", "r391", "r407", "r411", "r415", "r440", "r444", "r483", "r484", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r202", "r203", "r204", "r205", "r249", "r257", "r268", "r269", "r270", "r331", "r356", "r379", "r390", "r391", "r407", "r411", "r415", "r440", "r444", "r483", "r484", "r485", "r486", "r487" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses - related parties", "verboseLabel": "Accrued expenses - related parties" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r413" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r272", "r273", "r274", "r431", "r432", "r433", "r475" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r23", "r32", "r88", "r228" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount", "verboseLabel": "Amortization of Debt Discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r100", "r117", "r138", "r173", "r176", "r180", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r297", "r299", "r307", "r413", "r442", "r443", "r479" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r113", "r123", "r138", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r297", "r299", "r307", "r413", "r442", "r443", "r479" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL TRANSACTIONS" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r41", "r47" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r115", "r393" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r28", "r34", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "CASH, END OF PERIOD", "periodStartLabel": "CASH, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r28", "r87" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r118", "r119", "r120", "r138", "r155", "r156", "r158", "r160", "r163", "r164", "r187", "r206", "r209", "r210", "r211", "r215", "r216", "r233", "r234", "r236", "r240", "r247", "r307", "r392", "r425", "r428", "r434" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r16", "r95", "r105" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies - Note 7" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTIGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r55", "r200", "r201", "r387", "r441" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTIGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CommitmentsAndContigencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r431", "r432", "r475" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r413" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common, authorized 950,000,000 shares, 559,281,064 shares issued, and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r83", "r396" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "BASIS OF CONSOLIDATION" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r37", "r38", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common stock converted amount" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": { "auth_ref": [ "r4", "r62" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.", "label": "Series D Convertible Preferred mandatory redeemable, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively" } } }, "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockTermsOfConversion": { "auth_ref": [ "r3", "r4", "r62", "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for preferred stock.", "label": "Convertible preferred stock terms of conversion" } } }, "localname": "ConvertiblePreferredStockTermsOfConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r59", "r136", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r226", "r229", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r56", "r217" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r15", "r89", "r227" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r124", "r404", "r476" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt due date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred tax asset, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r82", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r82", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Temporary differences" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r32", "r53" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r121", "r208", "r209", "r210", "r214", "r215", "r216", "r321", "r394", "r430" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from the sale of assets - current portion" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r133", "r146", "r147", "r148", "r149", "r150", "r154", "r155", "r158", "r159", "r160", "r161", "r304", "r305", "r374", "r377", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic earnings (loss) per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r133", "r146", "r147", "r148", "r149", "r150", "r155", "r158", "r159", "r160", "r161", "r304", "r305", "r374", "r377", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted earnings (loss) per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "BASIC AND DILUTED EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r139", "r280", "r291" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Provision for income taxes, rates" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r61", "r111", "r128", "r129", "r130", "r141", "r142", "r143", "r145", "r151", "r153", "r162", "r189", "r248", "r272", "r273", "r274", "r287", "r288", "r303", "r308", "r309", "r310", "r311", "r312", "r313", "r317", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "verboseLabel": "INVESTMENT IN IMAGION BIOSYSTEMS" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystems" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r84", "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class Axis" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r225", "r250", "r251", "r252", "r253", "r254", "r255", "r306", "r328", "r329", "r330", "r405", "r406", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level Axis" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r225", "r250", "r255", "r306", "r328", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r225", "r250", "r255", "r306", "r329", "r405", "r406", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r225", "r250", "r251", "r252", "r253", "r254", "r255", "r306", "r330", "r405", "r406", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r225", "r250", "r251", "r252", "r253", "r254", "r255", "r328", "r329", "r330", "r405", "r406", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.", "label": "Cash exceeding insured amount" } } }, "localname": "FederalDepositInsuranceCorporationPremiumExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r185", "r186", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r231", "r245", "r301", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r403", "r436", "r437", "r438", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Amortization period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r21", "r50", "r424" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on fair value adjustment of investments", "verboseLabel": "Change in the unrealized fair value of securities" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r32" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "[Gain (Loss) on Sale of Investments]", "negatedLabel": "Loss on fair value adjustment of investments" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r32", "r57", "r58" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "[Gain (Loss) on Extinguishment of Debt]", "negatedLabel": "Gain on settlement of legal fees" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r20" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r139", "r281", "r282", "r285", "r289", "r292", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r77", "r79" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income Tax Examination, Likelihood of Unfavorable Settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r152", "r153", "r172", "r279", "r290", "r293", "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails1", "http://mahatten.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r127", "r277", "r278", "r282", "r283", "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r29", "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r31" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r31" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Notes payable balance reduced amount" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r31" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r52", "r357", "r358", "r359", "r361", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r90", "r98", "r131", "r171", "r315" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r108", "r385", "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Fair value of investment" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r106" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investment in equity securities", "periodEndLabel": "Balance as of December 31, 2021", "periodStartLabel": "Balance as of December 31, 2020", "verboseLabel": "Investment in equity securities" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetails", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT IN IMAGION BIOSYSTEMS" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENT" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r138", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r298", "r299", "r300", "r307", "r401", "r442", "r479", "r480" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r94", "r103", "r413", "r429", "r439", "r477" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r114", "r138", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r298", "r299", "r300", "r307", "r413", "r442", "r479", "r480" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r134" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r134" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r30", "r33" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r18", "r33", "r96", "r107", "r112", "r125", "r126", "r130", "r138", "r144", "r146", "r147", "r148", "r149", "r152", "r153", "r157", "r173", "r175", "r179", "r181", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r305", "r307", "r402", "r442" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "http://mahatten.com/role/ConsolidatedStatementsOfOperations", "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r2", "r93", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "[Notes and Loans Payable]", "verboseLabel": "Notes payable" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r2", "r93", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "[Notes Payable]", "verboseLabel": "Notes payable, net of discounts" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, net of discounts" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Note Payable [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "[Operating Costs and Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r173", "r175", "r179", "r181", "r402" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE:" } } }, "localname": "OperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards net" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r91", "r99", "r116" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PledgingPurposeAxis": { "auth_ref": [ "r339", "r412", "r414", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by pledging purpose of pledged asset owned.", "label": "Pledging Purpose [Axis]" } } }, "localname": "PledgingPurposeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PledgingPurposeDomain": { "auth_ref": [ "r339", "r412", "r414", "r474" ], "lang": { "en-us": { "role": { "documentation": "Pledging purpose of pledged asset owned." } } }, "localname": "PledgingPurposeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r4", "r62" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Convertible preferred stock, terms of conversion feature" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r233" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Capital stock, shares par value", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r60", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "[Preferred Stock, Redemption Price Per Share]", "verboseLabel": "Conversion price" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionTerms": { "auth_ref": [ "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.", "label": "Preferred stock redemption terms" } } }, "localname": "PreferredStockRedemptionTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r233" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r413" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A Convertible Preferred, authorized 182,525, no shares issued and outstanding, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r4", "r62" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Voting rights, description" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r122", "r198", "r199", "r395" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProFormaWeightedAverageSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average number of shares or units and dilutive common stock or unit equivalents outstanding in the calculation of proforma diluted earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Weighted average number diluted shares" } } }, "localname": "ProFormaWeightedAverageSharesOutstandingDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": { "auth_ref": [ "r24", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.", "label": "[Proceeds from Sale of Held-to-Maturity Securities]", "negatedLabel": "Sales of securities" } } }, "localname": "ProceedsFromSaleOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "auth_ref": [ "r426" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale of investments classified as other.", "label": "Proceeds from the sale of investments" } } }, "localname": "ProceedsFromSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r25" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds from sale of assets held for sale", "verboseLabel": "Proceeds from sale of assets held for sale" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSecuredNotesPayable": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Secured note" } } }, "localname": "ProceedsFromSecuredNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r54", "r104", "r376", "r413" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r54", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property and equipment useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r256", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r110", "r320", "r321", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction Axis" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r256", "r320", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r318", "r319", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r27" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayments for note payable", "terseLabel": "Payment in cash for repayment of note", "verboseLabel": "Note payable repayments" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r76", "r109", "r488" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "INTELLECTUAL PROPERTY / RESEARCH AND DEVELOPMENT" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r67", "r102", "r383", "r384", "r413" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r111", "r141", "r142", "r143", "r145", "r151", "r153", "r189", "r272", "r273", "r274", "r287", "r288", "r303", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "REVENUE RECOGNITION" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r132", "r138", "r169", "r170", "r174", "r177", "r178", "r182", "r183", "r184", "r187", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r215", "r216", "r307", "r375", "r442" ], "calculation": { "http://mahatten.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Minimum Royalty Payment" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/LicenseAgreementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Strike price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Summary of deferred tax assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of basic and diluted earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Provision for income taxes differs from amount computed by applying U.S. federal statutory tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r69", "r70", "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Summary of Company's stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsequentEventsTextBlock": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.", "label": "Schedule of Subsequent Events [Table Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "ScheduleOfSubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of changes to the investment in Imagion" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/InvestmentInImagionBiosystemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Stock options available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number]", "periodEndLabel": "Number of Options Exercisable, Outstanding Ending Balance", "periodStartLabel": "Number of Options Exercisable, Outstanding Beginning Balance", "verboseLabel": "Number of Options Exercisable, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails", "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]", "negatedLabel": "Number of Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value]", "periodEndLabel": "Aggregate intrinsic value, Ending Balance", "periodStartLabel": "Aggregate intrinsic value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Number of Options, Outstanding Ending Balance", "periodStartLabel": "Number of Options, Outstanding Beginning Balance", "terseLabel": "Number of Options, Outstanding Beginning Balance", "verboseLabel": "Number of Options, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails", "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r259", "r260" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price, Exercised", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails", "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r258", "r265", "r266", "r267", "r268", "r271", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "STOCK BASED COMPENSATION" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "LEASES" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r41", "r135" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r118", "r119", "r120", "r138", "r155", "r156", "r158", "r160", "r163", "r164", "r187", "r206", "r209", "r210", "r211", "r215", "r216", "r233", "r234", "r236", "r240", "r247", "r307", "r392", "r425", "r428", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r17", "r61", "r111", "r128", "r129", "r130", "r141", "r142", "r143", "r145", "r151", "r153", "r162", "r189", "r248", "r272", "r273", "r274", "r287", "r288", "r303", "r308", "r309", "r310", "r311", "r312", "r313", "r317", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical", "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r141", "r142", "r143", "r162", "r360" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative", "http://mahatten.com/role/CapitalTransactionsDetails1", "http://mahatten.com/role/CapitalTransactionsDetailsNarrative", "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedBalanceSheetsParenthetical", "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://mahatten.com/role/InvestmentInImagionBiosystemsDetailsNarrative", "http://mahatten.com/role/NotesPayableDetailsNarrative", "http://mahatten.com/role/RelatedPartyTransactionsDetailsNarrative", "http://mahatten.com/role/SubsequentEventsDetailsNarrative", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails", "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r61", "r67", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Number of Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r5", "r61", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Fair value of common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r48", "r413", "r429", "r439", "r477" ], "calculation": { "http://mahatten.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets", "http://mahatten.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r68", "r137", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r248", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "NOTE 5 - CAPITAL TRANSACTIONS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r314", "r324" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r314", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r314", "r324" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r37", "r38", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Licenses purchased price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r185", "r186", "r231", "r245", "r301", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r436", "r437", "r438", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/CapitalTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r44", "r45", "r46", "r165", "r166", "r167", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "USE OF ESTIMATES" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted-average diluted shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r154", "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average basic shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://mahatten.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails1" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918418-209957", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121825205&loc=d3e27249-109313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 56 0001477932-23-002486-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-002486-xbrl.zip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α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end